US GAAP
Issues and Solutions for the Pharmaceuticals and Life Sciences Industries
Foreword

Accounting under US Generally Accepted Accounting Principles (US GAAP) continues to evolve and in today’s world where there is a growing demand for greater transparency and heightened regulatory scrutiny; the need to ensure the proper accounting for transactions has never been greater. At the same time convergence with IFRS is becoming a reality rather than a possibility. Many non-US companies have already transitioned to IFRS and the SEC may provide US companies with an opportunity to make a similar switch.

Many publications have discussed the broader implications of US GAAP and IFRS but, to date, none has addressed the particular accounting issues the pharmaceutical and life sciences sector faces. The aim of this publication is to highlight the industry-specific factors which need to be considered, and to provide an opinion on the most pertinent accounting solutions for commercial situations under US GAAP. Separate publications have been produced by us addressing IFRS and together with this publication provide a comprehensive picture of certain industry related matters that companies are addressing.

In reality, every company deals with accounting issues that should reflect the facts and circumstances of their particular situation. The solutions in this publication provide a framework for determining the appropriate accounting answer but individual fact patterns may give rise to a different answer. We cannot hope to address every situation that occurs – there is too much creativity in licensing arrangements to achieve that. Rather, the solutions cover several general situations. As new trends emerge, we will consider further editions of this publication.

We hope you find this publication useful in understanding the accounting for the transactions you encounter in your business. Further, we hope that by stimulating debate around these topics, we will encourage consistent practices by the pharmaceuticals and life sciences companies in financial reporting under US GAAP. This consistency will be critical to the continued acceptance and usefulness of pharmaceutical and life science entities’ financial statements.

Simon Friend
Global Pharmaceuticals and Life Sciences Leader
PricewaterhouseCoopers LLP, UK

Mark Simon
US Pharmaceuticals and Life Sciences Leader
PricewaterhouseCoopers LLP, US
Contents

The value chain and associated US GAAP accounting issues 6
1 Capitalisation of internal development costs: timing 8
2 Capitalisation of internal development costs when regulatory approval has been obtained in a similar market 9
3 Capitalisation of development costs for generics 10
4 Development expenditure once capitalisation criteria are met 11
5 Examples of research and development costs 12
6 Useful economic lives of intangibles 13
7 Commencement of amortisation 14
8 Indefinite-life intangible assets 15
9 Indications and timing of impairment for intangibles 16
10 Exchange of intangible assets with no continuing involvement 17
11 Exchange of intangible assets with continuing involvement 18
12 Accounting for receipt of listed shares in exchange for a patent 19
13 Accounting for receipt of unlisted shares in exchange for a patent 20
14 Accounting for receipt of shares subject to trading restrictions in exchange for a patent 21
15 Complex arrangements for in-licensing agreements including capitalisation 22
16 Upfront payments to conduct research with access to the research 23
17 Payments made to conduct research and/or development 24
18 Payments received to conduct development 25
19 Upfront payments received to conduct development: initial recognition 26
20 Upfront payments received to conduct development: interim recognition 27
21 Upfront payments received to conduct development: completion 28
22 Donation payment for research 29
23 Loans received to fund research and development purposes 30
24 Segmental reporting of internal research and development 31
25 Segmental reporting of external research and development 32
26 Treatment of trial batches in development 33
27 Carrying value of property, plant and equipment 34
28 Treatment of validation batches 35
29 Carrying value of inventory 36
30 Treatment of development supplies 37
31 Treatment of inventory of ‘in-development’ drugs 38
32 Treatment of inventory of ‘in-development’ generic drugs 39
33 Advertising and promotional expenditure 40
34 Presentation of co-marketing expenses 41
35 Presentation of co-marketing income 42
36 Development of alternative indications 43
37 Line extension development costs 44
38 Cost incurred for performance comparisons 45
39 Development costs for limited markets 46
40 Cost-plus contract research arrangements 47
41 Fixed-fee contract research arrangements 48
42 Patent protection costs
43 Accounting for research which results in a development candidate
44 Third-party development of own intellectual property
45 Joint development of own intellectual property
46 External development of own intellectual property with buy-back options
47 Collaboration agreement to develop a drug – separable arrangements
48 Exchange of listed shares for a patent
49 Accounting for acquired early-stage projects
50 Cost of collaboration arrangements
51 Production technology development expenditure
52 Bifurcating components of a collaboration agreement
53 Development loan – market terms
54 Development loan – below market terms
55 Sales target milestone with fair royalty
56 Annual sales target milestone with fair royalty
57 Sales target milestone with below-market royalty
58 Sales target milestone with no royalty
59 Abnormal validation costs
60 Impairment of development costs prior to use
61 Impairment of development cost after regulatory approval
62 Single market impairment accounting
63 Impairment of an acquired early-stage project
64 Reversals of impairment loses (cost model)
65 Impairment testing and useful life
66 Amortisation method of development – intangible assets
67 Amortisation life of development – intangible assets
68 Presentation of capitalised development costs
69 Recognition of raw materials as inventory until a decision is made about its usage
70 Pre-launch inventory produced before filing
71 Net costs of validation batches sold
72 Net gain on sale of validation batches sold
73 Accounting for vaccine cultures in manufacturing of pharmaceutical products
74 Receipts for out-licensing
75 Receipts for conducting development
76 Revenue from collaboration arrangements
77 Payments received to conduct development – continuing involvement
78 Advertising and promotion costs
79 Segmental reporting for external research & development expenditure
80 Accounting for the cost of free samples
81 Classification of co-promotion royalties
82 Presentation of development supplies
Contacts
The value chain and associated US GAAP accounting issues

Capitalisation and amortisation

Capitalisation of internal development costs: timing
Capitalisation of internal development costs when regulatory approval has been obtained in a similar market
Capitalisation of development costs for generics
Development expenditure once capitalisation criteria are met
Examples of research and development costs
Useful economic lives of intangibles
Commencement of amortisation
Indefinite-life intangible assets
Indications and timing of impairment for intangibles
Development of alternative indications
Line extension development costs
Development costs for limited markets
Collaboration agreement to develop a drug – separable arrangements
Exchange of listed shares for a patent
Accounting for acquired early-stage projects
Cost of collaboration arrangements
Bifurcating components of a collaboration agreement
Impairment of development costs prior to use
Impairment of development costs after regulatory approval
Amortisation method of development – intangible assets
Amortisation life of development – intangible assets
Presentation of capitalised development costs

Externally sourced R&D

Exchange of intangible assets with no continuing involvement
Exchange of intangible assets with continuing involvement
Accounting for receipt of listed shares in exchange for a patent
Accounting for receipt of unlisted shares in exchange for a patent
Accounting for receipt of shares subject to trading restrictions in exchange for a patent
Complex arrangements for in-licensing agreements including capitalisation
Upfront payments to conduct research with access to the research
Payments made to conduct research and/or development
Cost-plus contract research arrangements
Fixed-fee contract research arrangements
Third-party development of own intellectual property
External development of own intellectual property with buy-back options

Research & Development
<table>
<thead>
<tr>
<th>R&amp;D related issues</th>
<th>Manufacture</th>
<th>Sales &amp; Marketing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Payments received to conduct development</td>
<td>Carrying value of property, plant and equipment</td>
<td>Advertising and promotional expenditure</td>
</tr>
<tr>
<td>Upfront payments received to conduct development: initial recognition</td>
<td>Treatment of validation batches</td>
<td>Presentation of co-marketing expenses</td>
</tr>
<tr>
<td>Upfront payments received to conduct development: interim recognition</td>
<td>Carrying value of inventory</td>
<td>Presentation of co-marketing income</td>
</tr>
<tr>
<td>Upfront payments received to conduct development: completion</td>
<td>Treatment of development supplies</td>
<td>Cost incurred for performance comparisons</td>
</tr>
<tr>
<td>Donation payment for research</td>
<td>Treatment of inventory of ‘in-development’ drugs</td>
<td>Sales target milestone with fair royalty</td>
</tr>
<tr>
<td>Loans received to fund research and development purposes</td>
<td>Treatment of inventory of ‘in-development’ generic drugs</td>
<td>Annual sales target milestone with fair royalty</td>
</tr>
<tr>
<td>Segmental reporting of internal research and development</td>
<td>Patent protection costs</td>
<td>Sales target milestone with below-market royalty</td>
</tr>
<tr>
<td>Segmental reporting of external research and development</td>
<td>Production technology development expenditure</td>
<td>Sales target milestone with no royalty</td>
</tr>
<tr>
<td>Treatment of trial batches in development</td>
<td>Abnormal validation costs</td>
<td>Single market impairment accounting</td>
</tr>
<tr>
<td>Accounting for research which results in a development candidate</td>
<td>Recognition of raw materials as inventory until a decision is made about its usage</td>
<td>Reversals of impairment losses (cost model)</td>
</tr>
<tr>
<td>Joint development of own intellectual property</td>
<td>Pre-launch inventory produced before filing</td>
<td>Impairment testing and useful life</td>
</tr>
<tr>
<td>Development loan – market terms</td>
<td>Net costs of validation batches sold</td>
<td>Advertising and promotion costs</td>
</tr>
<tr>
<td>Development loan – below market terms</td>
<td>Net gain on sale of validation batches sold</td>
<td>Accounting for the cost of free samples</td>
</tr>
<tr>
<td>Impairment of an acquired early-stage project</td>
<td>Accounting for vaccine cultures in manufacturing of pharmaceutical products</td>
<td>Classification of co-promotion royalties</td>
</tr>
<tr>
<td>Receipts for out-licensing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receipts for conducting development</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue from collaboration arrangements</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Payments received to conduct development – continuing involvement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Segmental reporting for external research &amp; development expenditure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presentation of development supplies</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
1. Capitalisation of internal development costs: timing

Background
A company is developing a vaccine for HIV that has successfully completed Phases 1 and 2 of clinical testing. The drug is now in Phase 3 of clinical testing. Management still has significant concerns about securing regulatory approval and has not started manufacturing or marketing the vaccine.

Relevant guidance
Research and development costs should be expensed when incurred [FAS 2R.12].

How should management account for research and development costs incurred on this project? Would the answer change if the drug is similar to other drugs the entity has successfully developed in the past and management believes it will be favourably treated by the regulatory authority?

Solution
Costs to perform research and development (R&D), including internal development costs, should be expensed as incurred regardless of past history with similar drugs or regulatory authority approval expectations. There is no capitalisation of internal costs for R&D under US GAAP.
2. Capitalisation of internal development costs when regulatory approval has been obtained in a similar market

Background
Scenario 1: An entity has obtained scientific regulatory approval for a new respiratory drug in Country Agara. It is now progressing through the additional development procedures necessary to gain approval in Country Belan. Management believes that achieving regulatory approval in this secondary market is a formality. Mutual recognition treaties and past experience show that Belan’s authorities rarely refuse approval for a new drug that has been approved in Agara.

Scenario 2: An entity has obtained scientific regulatory approval for a new AIDS drug in Country Spartek and is progressing through the additional development procedures necessary to gain approval in Country Oceana. Experience shows that significant additional clinical trials will be necessary to meet the Oceanese scientific regulatory approval requirements. Some drugs accepted in Spartek have not been accepted for sale in Oceana, even after additional clinical trials.

Should the development costs in each scenario be capitalised?

Solution
No, the company should expense development costs as incurred pursuant to FAS 2. Probability of success and past history do not impact the requirement to expense research and development costs as incurred.

Relevant guidance
Research and development costs should be expensed when incurred [FAS 2R.12].
3. Capitalisation of development costs for generics

Background
An entity is developing a generic version of a painkiller that has been sold in the market by another company for many years. The technical feasibility of the asset has already been established because it is a generic version of a product that has already been approved, and its chemical equivalence has been demonstrated. The lawyers advising the entity do not anticipate that any significant difficulties will delay the process of obtaining commercial regulatory approval.

Relevant guidance
Research and development costs should be expensed when incurred [FAS 2R.12].

Should management capitalise the development costs at this point?

Solution
No, research and development costs should be expensed when incurred.
4. Development expenditure once capitalisation criteria are met

Background

Scenario 1: MagicCure has obtained scientific regulatory approval for a new respiratory drug and is now incurring expenditure to educate its sales force and perform market research.

Scenario 2: DeltaB has determined that it has met the six criteria for capitalisation for a vaccine delivery device. It is now continuing expenditure on the device to add new functionality. The development of this device will require new scientific regulatory approval.

Relevant guidance

Research and development costs should be expensed when incurred [FAS 2R.12]. Expenses are outflows or other using up of assets or incurrences of liabilities (or a combination of both) from delivering or producing goods, rendering services, or carrying out other activities that constitute the entity’s ongoing major or central operations [CON 6R80].

Should the managements of MagicCure and DeltaB capitalise these costs?

Solution

MagicCure should expense sales and marketing expenditures such as training a sales force or performing market research as incurred.

DeltaB should not capitalise the expenditure it incurs to add new functionality as these costs would be considered research and development expenditures for the new indications and would be expensed as incurred. Note that the six criteria for capitalisation referred to in the Background is not applicable for US GAAP.
5. Examples of research and development costs

Background

A laboratory is developing a drug to cure SARS. But management is unsure what costs to include as R&D expenditures.

Relevant guidance

Research and development costs are defined in FAS R.8 and examples of such costs are presented in FAS 2R9 and R10.

What kinds of expenditure can be considered research and development costs in the pharmaceutical industry?

Solution

The following are examples of activities that typically would be considered research and development expenditures:

- Laboratory research aimed at discovery of new knowledge.
- Searching for applications of new research findings or other knowledge.
- Conceptual formulation and design of possible product or process alternatives.
- Testing in search for or evaluation of product or process alternatives.
- Modification of the formulation or design of a product or process.
- Design, construction, and testing of pre-production prototypes and models.
- Design of tools, jigs, molds, and dies involving new technology.
- Design, construction, and operation of a pilot plant that is not of a scale economically feasible to the enterprise for commercial production.
- Engineering activity required to advance the design of a product to the point that it meets specific functional and economic requirements and is ready for manufacture [FAS 2R.9].
- Expenditures in the above activities could include materials, equipment or facility charges, compensation and benefits for personnel, intangible assets purchased from others (to the extent that they do not have alternative use or technological feasibility), the cost of contract services performed by others, and a reasonable allocation of indirect costs.
6. Useful economic lives of intangibles

Background
A laboratory has acquired a license to manufacture and sell a newly approved pharmaceutical drug.

What factors should management consider in its assessment of the useful life of the intangible asset (including ongoing reassessment of useful lives)?

Solution
Internal costs and external costs for R&D incurred prior to regulatory approval are generally expensed under US GAAP. External costs to acquire a license, product or right paid upon or after regulatory approval should be capitalised as intangibles pursuant to FAS 142. The useful life of assets, particularly those valued using a cash flow model, often cover the period over which substantially all of the cash flows of the asset are expected to occur. Management must also consider a number of factors that are relevant to all industries and the guidance in FAS 142R.11 when determining the useful life of an intangible asset. In addition to these factors, it should consider industry-specific factors, such as the following:

- Duration of the patent right or licence of the product;
- Redundancy of a similar medication/device due to changes in market preferences;
- Impact of bad publicity on a brand name (for example, a significant fall in sales arising from side-effects of a product or a product recall);
- Unfavourable court decisions on claims from product users;
- Regulatory decisions over patent rights or licences;
- Development of new drugs treating the same disease;
- Changes in the environment that make the product ineffective (for example, a mutation in the virus that is causing a disease, which renders it stronger);
- Changes or anticipated changes in participation rates or reimbursement policies of insurance companies; and
- Changes in government reimbursement or policies (i.e. Medicare, Medicaid) for drugs and other medical products.

Relevant guidance
The accounting for a recognised intangible asset is based on its useful life to the reporting entity.

The useful life of an intangible asset to an entity is the period over which the asset is expected to contribute directly or indirectly to the future cash flows of that entity [FAS 142R.11].

The remaining useful life of an intangible asset should be reviewed each reporting period to determine whether events and circumstances warrant a revision to the remaining period of amortisation [FAS 142R14].
7. Commencement of amortisation

Background
A company acquired a compound for $5 million on 1 January 20X3. The entity amortises its intangible assets on a straight-line basis over the estimated useful life of the asset. The entity receives regulatory and marketing approval on 1 March 20X4 and starts using the compound in its production process on 1 June 20X4.

Relevant guidance
The useful life of an intangible asset to an entity is the period over which the asset is expected to contribute directly or indirectly to the future cash flows of that entity. The method of amortising an intangible asset should reflect the pattern in which economic benefits of the intangible are used up [FAS 142R.11&12].

When should it begin amortising its intangible assets?

Solution
Because the compound was acquired prior to regulatory approval, the payment would be expensed under US GAAP as research and development (assuming there is no alternative future use). Had the compound been acquired after regulatory approval, the entity should begin amortising the intangible asset on the date when it is available for its expected use. This would generally be the acquisition date.
8. Indefinite-life intangible assets

Background
Management of a pharmaceutical entity has acquired an intangible asset that it believes has an indefinite useful life and has decided not to amortise it.

Relevant guidance
If no legal, regulatory, contractual competitive economic or other factors limit the useful life of an intangible asset, the useful life of the asset shall be considered to be indefinite [FAS 142R.11]. If an intangible asset is determined to have an indefinite useful life, it shall not be amortised until its useful life is determined to be no longer indefinite [FAS 142R.16].

An entity shall evaluate the remaining useful life of an intangible asset that is not being amortised each reporting period to determine whether events and circumstances continue to support an indefinite useful life. An intangible asset that is not subject to amortisation shall be tested for impairment annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired [FAS 142R.16 & R.17].

Can management regard the asset as having an indefinite life, and how should management account for it?

Solution
Yes, management can regard an asset as having an indefinite life in accordance with FAS 142. However, even though the asset is not amortised, management is required to test it for impairment, by comparing its fair value with its carrying value both annually and more often if there is an indication the intangible asset may be impaired (i.e. a triggering event occurs) [FAS 142R.17].

Pharmaceutical intangible assets that might be regarded as having an indefinite life could include acquired brands (i.e. over the counter products) or generic products. Technological and medical advances will reduce the number of situations where an indefinite life would apply. As a result of limited patent lives, only in exceptional cases would pharmaceutical products have indefinite economic lives.
9. Indications and timing of impairment for intangibles

Background
An entity has capitalised the cost of acquiring a respiratory product in Phase 3 development that it is not amortising, as it is not available for use.

What indicators of impairment should management consider?

Relevant guidance
An intangible asset should be evaluated for impairment as part of its assigned asset group if events or changes in circumstances indicate that the asset might be impaired [FAS R.8 and R.10]. An impairment loss should only be recognised if the carrying amount of the asset group is not recoverable from estimated undiscounted future cash flows of the asset group. In such cases, an impairment loss shall be recognised in an amount equal to the excess of the asset group’s carrying value over its fair value [FAS 144R.7].

Solution
There would be no asset recorded under US GAAP for products acquired prior to regulatory approval; however, if the product had been acquired subsequent to regulatory approval, FAS 144R.8 provides several examples of events or changes in circumstance (not all-inclusive) that management should consider when assessing whether an intangible asset should be tested for impairment.

Management of pharmaceutical and life sciences entities should also consider other industry-specific indicators, including:
• Development of a competing drug;
• Changes in the legal framework covering patents, rights or licences;
• Failure of the drug’s efficacy after a mutation in the disease that it is supposed to treat;
• Advances in medicine and/or technology that affect the medical treatments;
• Lower than predicted sales;
• Impact of publicity over brand names;
• Change in the economic lives of similar assets (see Solution 123.6 for discussion of useful lives);
• Relationship with other intangible or tangible assets; and
• Changes or anticipated changes in participation rates or reimbursement policies of insurance companies, Medicare and governments for drugs and other medical products.
10. Exchange of intangible assets with no continuing involvement

Background

Egram is developing a hepatitis vaccine compound. Fiorel is developing a measles vaccine compound. Egram and Fiorel enter into an agreement to swap the two products. Egram and Fiorel will not have any continuing involvement in the products that they have exchanged. The fair value of Egram’s compound has been assessed as 3 million. The carrying value of the compound given up is zero as Egram has expensed all research and development costs associated with this unapproved product.

Relevant guidance

An intangible asset may be acquired in exchange for a non-monetary asset or assets. The cost of the acquired intangible asset is measured at fair value unless:

(a) the exchange transaction has no commercial substance,
(b) the fair value of neither the asset received nor given up is reliably measurable or
(c) the transaction is an exchange of a product held for sale in the ordinary course of business for a product to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. [APB 9R.20 as amended by FAS 5].

The cost of the asset received should be based on the fair value of the asset surrendered unless the fair value of the asset received is more clearly evident [APB 9R.8].

A non-monetary exchange has commercial substance if the future cash flows of the entity are expected to change significantly as a result of the exchange. [FAS 153R.1].

Solution

In the situations noted, it is assumed that the exchange(s) has commercial substance; therefore, Egram’s management should recognise the compound received at the fair value of the compound given up, which is LC 3 million. The transaction is assumed to have commercial substance in accordance with FAS 153, since future cash flows of both entities will change significantly once the vaccines are approved. Management should also recognise a gain on the exchange of LC 3 million. This gain does not take into account, or rather is not adjusted, for any difference between the fair market value of the asset given up and what the other company felt the FMV of their asset was, again, they are assumed to be equal.

Egram should immediately expense the value ascribed to the received compound as a research and development costs since the compound is not approved. If the compound was approved, Egram would capitalise LC 3 million to this asset and amortise over its useful life.
11. Exchange of intangible assets with continuing involvement

Background

Entity Giant is developing a hepatitis vaccine compound. Entity Hercules is developing a measles vaccine compound. Giant and Hercules enter into an agreement to swap these two products. Under the terms of the agreement, Giant will retain the marketing rights to its drug for all Asian countries. The fair value of Giant's compound has been assessed as $3 million, including $0.2 million relating to the Asian marketing rights. The carrying amount of the compound is $0.5 million.

Relevant guidance

An intangible asset may be acquired in exchange for a non-monetary asset or assets. The cost of the acquired intangible asset is measured at fair value unless:

(a) the exchange transaction has no commercial substance,
(b) the fair value of neither the asset received nor given up is reliably measurable or
(c) the transaction is a an exchange of a product held for sale in the ordinary course of business for a product to be sold in the same line of business to facilitate sales to customers other than the parties to the exchange. [APB 9R.20 as amended by FAS 5].

The cost of the asset received should be based on the fair value of the asset surrendered unless the fair value of the asset received is more clearly evident [APB 9R.8].

A non-monetary exchange has commercial substance if the future cash flows of the entity are expected to change significantly as a result of the exchange. [FAS 153R.1].

Solution

In the situations noted, it is assumed that the exchange(s) has commercial substance; therefore, Giant’s management should recognise the compound received at the fair value of the compound given up, which is $2.8 million ($3.0 million - $0.2 million). The fair value of $0.2 million relating to the marketing rights is excluded from the calculation because the rights have not been sold. Management should also recognise a gain on the exchange of $2.8 million (consideration received of $2.8 million less assumed carrying value of zero). Giant should immediately expense the value ascribed to the received compound as a research and development costs since the compound is not approved. If the compound was approved, Giant would capitalise LC 2.8 million to this asset and amortise over its useful life.

This scenario assumes Giant has no continuing involvement in the development of the hepatitis vaccine compound subsequent to the exchange which may be rare in practice due to involvement in steering committees, future development efforts, buy-back rights, etc. If Giant had continuing involvement in the hepatitis vaccine, it would need to consider whether the gain would need to be deferred and recognised over the continuing involvement period.

How should Giant’s management account for the swap of vaccine products (comprising intellectual property), assuming that the transaction has commercial substance?
Background
Jerome agrees to acquire a patent from pharmaceutical group Kupla in order to develop a more complex drug. Jerome will pay for the right it acquires by giving Kupla 5% of its shares (which are listed). The listed shares represent the fair value of the patent. If Jerome is successful in developing a drug and bringing it to the market, Kupla will also receive a 5% commission on all sales. Kupla’s management expects to classify the shares as available for sale.

Relevant guidance
An investor should record its investment in the stock of an investee at its cost [APB 8R.6a]. Equity securities that have readily determinable fair values shall be classified as trading securities or available for sale securities [FAS 5R.].

The cost of the asset received should be based on the fair value of the asset surrendered unless the fair value of the asset received is more clearly evident [APB 29R.18].

Solution
Kupla’s management should initially recognise the shares received as available-for-sale securities at their fair value. Kupla’s management should also derecognise the patent that is transferred to Jerome, and should recognise the gain arising from the sale of the patent. The fair value of the shares received represents the amount of the consideration received and would be used to measure this transaction as it is more readily determinable (market quoted value) than is the value of the patent given up. Transaction costs would be recorded as a reduction of the gain on the sale of the patent.

Kupla should not yet recognise any asset relating to the future royalty stream from the potential sales of the drug, because this stream of royalties is contingent upon the successful development of the drug. The revenue will be recognised on an accrual basis, as the royalties are earned.

Following the rules for available-for-sale securities, Kupla should subsequently measure the shares at fair value at each balance sheet date. Movements in fair value should be recognised in equity, except for other than temporary impairment losses, which are charged to the income statement. Any subsequent recovery in the value of the security after the impairment loss would not reverse the impairment loss but would rather be recorded in equity. Management should also provide relevant disclosures relating to the key characteristics of the shares (i.e. restrictions).

How should Kupla’s management account for the shares it receives?
Background
A company Rossel agrees to acquire a patent from pharmaceutical group Kupla in order to try to develop a more complex drug. Rossel will pay for the right it acquires by giving Kupla 10% of the shares in an unlisted subsidiary. If Rossel is successful in developing the drug and bringing it to the market, Kupla will receive a 5% commission on all sales. Management expects to classify these shares as available-for-sale.

Relevant guidance
An investor should record its investment in the stock of an investee at its cost [APB 8R.6a]. Equity securities that have readily determinable fair values shall be classified as trading securities or available for sale securities [FAS 5R.].

The cost of the asset received should be based on the fair value of the asset surrendered unless the fair value of the asset received is more clearly evident [APB 29R.18].

Solution
Generally, the fair value of the patent given up (i.e. an asset) will be more readily determinable than the fair value of the shares because these shares are of an unlisted subsidiary. FAS 115 states that fair value is only deemed readily determinable if sales prices or bid-and-asked quotations are currently available on a securities exchange registered with the Securities and Exchange Commission (SEC) or in the over-the-counter market, or similar foreign market.

Consequently, Kupla’s management would generally conclude that the fair value of the shares is the same value as the patent given up. Kupla’s management should also derecognise the patent that is transferred to Rossel and should recognise the gain arising from the sale of the patent (fair value less carrying value of the patent). Transaction costs would be recorded as a reduction of the gain on the sale of the patent.

Kupla should not yet recognise any asset relating to the future royalty stream from the potential sales of the drug, because this stream of royalties is contingent upon the successful development of the drug. The revenue will be recognised on an accrual basis, as the royalties are earned.
14. Accounting for receipt of shares subject to trading restrictions in exchange for a patent

Background
Landra acquires a patent from pharmaceutical group Mixan in order to develop a more complex drug. Landra pays for the right it acquires by giving Mixan 5% of its listed shares. This does not give Mixan significant influence over Landra. The shares received by Mixan will have the following restriction: during the first two years, Mixan can only sell the shares to a third party at a price fixed in the agreement with Landra. Mixan’s management expects to classify these shares as available-for-sale.

Relevant guidance
An investor should record its investment in the stock of an investee at its cost [APB 18R.6a]. Equity securities that have readily determinable fair values shall be classified as trading securities or available for sale securities [FAS 5R.]. The price in the principal market used to measure the fair value of the asset or liability shall not be adjusted for transaction costs [FAS 57R.9] (Note that FAS 157 is effective for fiscal years beginning after November 15, 2007).

For individual securities classified as either available-for-sale, an enterprise shall determine whether a decline in fair value below the amortised cost basis is other than temporary. If the decline in fair value is judged to be other than temporary, the cost basis of the individual security shall be written down to fair value as a new cost basis and the amount of the write-down shall be included in earnings (that is, accounted for as a realised loss). The new cost basis shall not be changed for subsequent recoveries in fair value. Subsequent increases in the fair value of available-for-sale securities shall be included in other comprehensive income; subsequent decreases in fair value, if not an other-than-temporary impairment, also shall be included in other comprehensive income. [FAS 5R.6]

The cost of the asset received should be based on the fair value of the asset surrendered unless the fair value of the asset received is more clearly evident [APB 9R.8]. Fair value measurements should consider attributes specific to the asset and restrictions, if any, on the sale or use of the asset at the measurement date [FAS 57R.6].

Solution
Mixan’s management should initially measure the listed shares received as available-for-sale securities at their quoted market price given that their value is readily determinable. The quoted market price should be adjusted for restrictions if a marketplace participant would consider those restrictions in determining the fair value of the securities. Note that FAS 157 is effective for years beginning after November 15, 2007. Prior to that date, restrictions are generally not considered in the determination of fair value of acquired shares.

Following the rules for available-for-sale securities, Mixan should subsequently measure the shares at fair value at each balance sheet date. Movements in fair value should be recognised in equity, except for other than temporary impairment losses, which are charged to the income statement. Any subsequent recovery in the value of the security after the impairment loss would not reverse the impairment loss but would rather be recorded in equity. Management should also provide relevant disclosures relating to the key characteristics of the shares (i.e. restrictions). Mixan should derecognise the intangible asset represented by the patent transferred to Landra and recognise any resulting gain or loss in the income statement.

How should Mixan’s management account for the shares it receives?
15. Complex arrangements for in-licensing agreements including capitalisation

**Background**

Entities Regal and Simba enter into an agreement in which Regal will licence Simba’s know-how and technology (which has a fair value of 3 million) to manufacture a compound for AIDS. It cannot use the know-how and technology for any other project. Regal’s management has not yet concluded that economic benefits are likely to flow from this compound or that relevant regulatory approval will be achieved. Regal will use Simba’s technology in its facilities for a period of three years. Simba will have to keep the technology updated and in accordance with Regal’s requirements. The agreement stipulates that Regal make a non-refundable payment of 3 million to Simba for access to the technology. Simba will also receive a 20% royalty from sales of the protein compound.

**Relevant guidance**

Research and development costs should be expensed when incurred [FAS 2R.12].

If an asset acquired to be used in a current R&D activity has no alternative future use, the portion of the purchase price allocated to that asset be immediately charged to income by the combined enterprise [AICPA Practice Aid: Assets Acquired in a Business Combination Used in R&D – R3.1.01]

**How should Regal’s management account for the in-licensing agreement?**

**Solution**

Regal’s management should expense the LC 3 million when incurred as R&D expense since the know-how has no other alternative future use.

When the drug is sold, Regal pays Simba 20% of sales. These payments are presented in the income statement, by nature (as part of operating expenses) or by function (generally as cost of sales). The method of presentation of expenses in the income statement should be applied consistently.
16. Upfront payments to conduct research with access to the research

Background
Astro engages a contract research organisation (CRO) to perform research activities for a period of two years in order to obtain know-how and try to discover a cure for AIDS. The CRO is well known in the industry for having modern facilities and good practitioners dedicated to investigation. The CRO receives a non-refundable, upfront payment of 3 million in order to carry out the research under the agreement. It will have to present a quarterly report to Astro with the results of its research. Astro has full rights of access to all the research performed, including control of the research undertaken on the potential cure for AIDS. The CRO has no rights to use the results of the research for its own purposes.

Relevant guidance
All research and development costs encompassed by this Statement shall be charged to expense when incurred [FAS 2R.12].
Non-refundable advance payments for future research and development activities should be capitalised until the goods have been delivered or the related services have been performed. [EITF 07-03].

Solution
Although the payment is non-refundable, Astro will receive a future benefit as the CRO performs the research and should capitalise the upfront payment and amortise it as R&D expense as the CRO performs the research activities. Astro should continue to evaluate whether they expect the goods to be delivered or services to be rendered each reporting period to assess recoverability of the asset.
17. Payments made to conduct research and/or development

Background

Alpha, a small pharmaceutical company, contracts with the much larger BetaX to develop a new medical treatment for migraines over a five-year period. Alpha is engaged only to provide research and development services and will periodically have to update BetaX with the results of its work. BetaX has exclusive rights over the development results. It will make 20 equal non-refundable quarterly payments of LC 250,000 (totalling LC 5 million), if Alpha can demonstrate compliance with the development programme. Payments do not depend upon the achievement of a particular outcome. Alpha’s management estimates the total cost will be LC 4 million.

In the first quarter of year one, Alpha incurs costs of 400,000, in line with its original estimate. Alpha is in compliance with the research agreement, including the provision of updates from the results of its work.

Relevant guidance

All research and development costs encompassed by this Statement shall be charged to expense when incurred [FAS 2R.12].

How should BetaX recognise the payments it makes Alpha?

Solution

BetaX should recognise research and development expense of LC 250,000 each quarter for as long as it authorises Alpha to continue performing the research. The straight-line method should be used for recognising the expense unless another method is more reflective of the effort performed by BetaX (i.e. proportionate performance).
18. Payments received to conduct development

Background

Alpha, a small pharmaceutical company, contracts with the much larger BetaX to develop a new medical treatment for migraine over a five-year period. Alpha is engaged only to provide development services and will periodically have to update BetaX with the results of its work. BetaX has exclusive rights over the development results. It will make 20 equal non-refundable payments of 250,000 (totalling 5 million), if Alpha can demonstrate compliance with the development programme. Payments do not depend upon the achievement of a particular outcome. Alpha’s management estimates the total cost will be 4 million.

In the first quarter of year one, Alpha incurs costs of 400,000, in line with its original estimate. Alpha is in compliance with the research agreement, including the provision of updates from the results of its work.

Relevant guidance

Service revenues should be recognised on a straight-line basis, unless evidence suggests that the revenue is earned or obligations are fulfilled in a different pattern, over the contractual term of the arrangement or the expected period, during which those specified services will be performed, whichever is longer [SAB 104, Topic 13R.3f.Q2].

Solution

If costs incurred are a reasonable representation of an output measure then Alpha should recognise the revenue on a proportional performance basis; otherwise, Alpha should recognise the revenue on a straight-line basis over the five-year period. This scenario assumes the development services are the only deliverable in the arrangement. If other deliverables existed, revenue should be allocated to each deliverable applying the guidance in EITF 00-21.

How should Alpha recognise the payments it receives from BetaX to conduct development?
19. Upfront payments received to conduct development: initial recognition

Background
CareB has appointed Devox to develop an existing compound on its behalf. Devox will have no further involvement in the compound after regulatory approval. CareB will retain full ownership of the compound (including intellectual rights), even after scientific regulatory approval is obtained. Devox will not participate in any further marketing or production arrangements. A milestone plan is included in the contract. CareB agrees to make the following non-refundable payments to Devox:

- 3 million on signing of the agreement;
- 1 million on filing for stage 3 clinical trial approval; and
- 2 million on securing scientific regulatory approval.

In addition, CareB will reimburse Devox for any expenditure incurred above 3 million prior to filing for stage 3 clinical trial approval.

Devox expects to incur costs totalling 3 million up to the point of filing for stage 3 clinical trial approval. But management cannot reliably estimate whether the compound will obtain stage 3 clinical trial approval or scientific regulatory approval.

Relevant guidance
Many arrangements require the customer to pay a certain amount of money at the start of the contract. These up-front payments are often characterised as non-refundable and are sometimes earmarked for “past services,” for “access” to some intangible right or for some general “rights.” Unless the up-front payment is in exchange for a product, service or right and represents the culmination of a separate earnings process, the up-front fee should be deferred over the longer of the contractual life of an arrangement or the customer relationship life. The customer’s perception of value received is paramount in this assessment. [SAB Topic 13].

How should Devox recognise the initial payment it has received from CareB?

Solution
Devox should record the initial payment as deferred income and recognise as income based on performance or on a straight line basis over the expected development period if development is performed evenly. At no point, however, should the revenue recorded exceed the amount of cash received. When the payment is initially received, no earnings process has been completed. No consideration should be given to the future milestone payments, as their receipt cannot be reliably estimated and no earnings process has been completed.
20. Upfront payments received to conduct development: interim recognition

**Background**
Devox is now in the process of fulfilling the contract with CareB outlined in the previous scenario. It has incurred 2 million in development costs from the inception of the contract on 1 March 20X1 through to 31 December 20X1, as projected in the original development plan.

**Relevant guidance**
Up-front fees, even if non-refundable, are earned as the products and/or services are delivered and/or performed over the term of the arrangement or the expected period of performance and generally should be deferred and recognised systematically over the periods that the fees are earned. A systematic method would be on a straight-line basis, unless evidence suggests that revenue is earned or obligations are fulfilled in a different pattern, in which case that pattern should be followed. Service revenue should be recognised on a straight-line basis, unless evidence suggests that the revenue is earned or obligations are fulfilled in a different pattern, over the contractual term of the arrangement or the expected period during which those specified services will be performed. [SAB Topic 13].

**Solution**
Devox should now recognise the deferred income it initially recorded. Devox should recognise the revenue on a straight-line basis or proportionally over the contract term based on the level of effort spent each period. Costs incurred may be an appropriate basis for measuring level of effort if the costs incurred are related to output measures such as man-hours or personnel costs. Initial set-up costs for materials, equipment or similar items should not be considered as they are generally not related to revenue generating activities. No consideration should be given to the future milestone payments, as their receipt cannot be reliably estimated and no earnings process has been completed.

It is important to note that CareB has no continuing involvement after the development phase in this scenario. If there was continuing involvement (i.e. co-marketing, manufacturing, steering committees), the terms of those contracts would need to be considered in determining the appropriate period to recognise the upfront payment as revenue.
21. Upfront payments received to conduct development: completion

Background

The compound on which Devox is working has now been filed for stage 3 clinical trial approval (Solution 123.19 and 123.20). CareB has paid the 1 million milestone payment specified in the development contract, in addition to the 3 million it paid on signing the contract. Devox has incurred costs of 3 million to reach this point, in line with original expectations, but management cannot reliably estimate whether it will be possible to obtain scientific regulatory approval for the compound.

Relevant guidance

Up-front fees, even if non-refundable, are earned as the products and/or services are delivered and/or performed over the term of the arrangement or the expected period of performance and generally should be deferred and recognised systematically over the periods that the fees are earned. A systematic method would be on a straight-line basis, unless evidence suggests that revenue is earned or obligations are fulfilled in a different pattern, in which case that pattern should be followed. Service revenue should be recognised on a straight-line basis, unless evidence suggests that the revenue is earned or obligations are fulfilled in a different pattern, over the contractual term of the arrangement or the expected period during which those specified services will be performed. [SAB Topic 13].

Solution

Devox should continue to recognise the upfront payment based on either the straight-line or proportionate performance method it selected in the previous scenario. Several acceptable models exist for recognising milestone payments including the following:

(1) Milestone method – Devox would recognise the milestone payment of LC 1,000,000 fully as revenue upon filing for stage 3 clinical trial approval. Generally to qualify for this method, the milestone events should have substance and represent the achievement of defined goals worthy of the payments. The following criteria could be used as guidance in making this judgemental assessment:

- Substantive effort is involved in achieving each milestone
- Milestone payments are reasonable in relation to the effort expended to achieve that milestone as well as the amount and level of effort relating to other milestone payments.
- A reasonable amount of time should pass between the up-front payment and the first milestone, as well as between successive milestones
- Consideration of the risk associated with each milestone

(2) Proportional performance model (analogy to EITF 91-6) - Revenue is recognised in an amount equal to the lesser of (a) the amount due under the contract, or (b) amount based on proportional performance to date.

(3) Contingency-adjusted performance model – Revenue is recognised based on the proportional performance to date at the time the milestone is achieved.

(4) Contract deferral model – The milestone payment is deferred and recognised over the remaining term of the contract. Care should be used when selecting this method as it significantly back-ends recognition of revenue under the arrangement.

If the proportionate performance method was used for recognising the upfront payment, that method would generally be selected for accounting for the milestone payment as well. This would be a policy election which should be consistently applied by Devox.
22. Donation payment for research

Background
Sherriff has made a non-refundable gift of LC 3 million to a university. The donation is to be used to fund research activities in the area of infectious diseases over a two-year period. Sherriff has no right to access the research findings.

Relevant guidance
Contributions made shall be recognised as expenses in the period made and as decreases of assets or increases of liabilities depending on the form of the benefits given. Unconditional promises to give cash are recognised as payables and contribution expenses [FAS 116R.18].

Sherriff proposes to recognise the donation as an intangible asset.

Solution
Management should not recognise the donation as an intangible asset, irrespective of whether or not the company has access to the research findings. The donation should be expensed when made or at the time an unconditional promise to give is made, whichever is sooner, in the appropriate line item in the income statement (generally selling, general and administrative). If the donation will be made over time, Sheriff should discount the obligation to its present value in accordance with APB 21.
23. Loans received to fund research and development purposes

Background
Pilax has obtained a loan from Qula, another pharmaceutical company, to finance the late-stage development of a drug to treat cancer. Qula will have co-marketing rights over any product that is developed. Pilax’s management has decided to capitalise all the development costs incurred after filing for scientific regulatory approval. Pilax applies the allowed alternative accounting treatment under IAS23 and capitalises borrowing costs on qualifying assets.

Relevant guidance
Interest shall be capitalised for the following types of assets (“qualifying assets”) [FAS 34R9]:
- Assets that are constructed or otherwise produced for an enterprise’s own use
- Assets intended for sale or lease that are constructed or otherwise produced as discrete projects
Investments accounted for by the equity method while the investee has activities in progress necessary to commence its planned principal activities.

Solution
Borrowing costs associated with costs for research and development projects are expensed as incurred as development costs and do not qualify as assets under US GAAP (FAS 34).
24. Segmental reporting of internal research and development

Background

Alpha produces and sells a certain therapeutic group of drugs which is reported as a separate business segment in its financial statements. It funds the majority of its R&D activities internally in order to develop new drugs. It does not provide any significant R&D to external parties.

Relevant guidance

An operating segment is a component of an enterprise that:
(a) engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise),
(b) whose operating results are regularly reviewed by the enterprise’s chief operating decision maker(s), and
(c) for which discrete financial information is available [FAS 131R, 10].

Should R&D activities be reported as a segment?

Solution

This determination depends on the manner in which Alpha’s chief operating decision maker (“CODM”) evaluates the business. If the R&D function recognises revenue for the services it provides to other components of the enterprise, the CODM regularly evaluates the revenues and operating results of the R&D function, and discrete financial information is available, the R&D function could be considered an operating segment. If this criteria is not met, costs of R&D activities should be assigned to Alpha’s other operating segments based on the manner in which the CODM evaluates the segments. In other words, if R&D costs are allocated to the segments for purposes of the CODM evaluating the performance of the segment, then such costs would be included in the segment measure of profit and loss. If the profit measure the CODM uses to evaluate the segments does not include R&D costs, then such costs would be included as a reconciling item, similar to unallocated corporate costs.
25. Segmental reporting of external research and development

Background
Laboratory B has R&D facilities, which it uses to perform contract investigation activities for other laboratories and pharmaceutical companies. 60% of the laboratory’s revenues are earned from external customers - and these external revenues represent 15% of the organisation’s total revenues.

Relevant guidance
An operating segment is a component of an enterprise that (a) engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise’s chief operating decision maker(s), and (c) for which discrete financial information is available [FAS 131R. 10].

An enterprise shall report separately information about an operating segment that meets any of the following quantitative thresholds:

(a) its reported revenue, including both sales to external customers and intersegment sales or transfers, is 10% or more of the combined revenue, internal and external, of all operating segments;

(b) the absolute amount of its reported profit or loss is 10% or more of the greater, in absolute amount, of the combined reported profit of all operating segments that did not report a loss or the combined reported loss of all operating segments that did report a loss; or

(c) its assets are 10% or more of the combined assets of all operating segments [FAS 131R. 18].

Should it report its R&D activities as a business segment?

Solution
This determination depends on the manner in which Laboratory B’s chief operating decision maker (“CODM”) evaluates the business. If the R&D function recognises revenue for the services it provides to other components of the enterprise, the CODM regularly evaluates the revenues and operating results of the R&D function, and discrete financial information is available, the R&D function could be considered an operating segment. If this criteria is not met, the costs of R&D activities should be assigned to Alpha’s other operating segments based on the manner in which the CODM evaluates the segments. In other words, if R&D costs are allocated to the segments for purposes of the CODM evaluating the performance of the segment, then such costs would be included in the segment measure of profit and loss. If the profit measure the CODM uses to evaluate the segments does not include R&D costs, then such costs would be included as a reconciling item, similar to unallocated corporate costs.
26. Treatment of trial batches in development

Background
A laboratory is manufacturing a stock of 20,000 doses (trial batches) of a newly developed drug, using various raw materials. The doses can only be used in patient trials during Phase 3 clinical testing, and they cannot be used for any other purpose. The raw materials can be used in the production of other drugs.

Relevant guidance
The costs of materials, whether from the enterprise’s normal inventory or acquired specially for research and development activities, that are acquired for research and development activities and have no alternative future uses (in research and development projects or otherwise) shall be expensed as incurred [FAS 2R. 11a].

How should management account for the raw materials and trial batches?

Solution
Management should initially capitalise the raw materials acquired in inventory as the materials have alternative future use in the production of an approved drug. As the trial batches do not have any alternative future use and the technical feasibility of the drug is not proven, the trial batches (including identified raw materials) should be charged to development expense when they are produced.
27. Carrying value of property, plant and equipment

Background
When assessing the carrying value of property, plant and equipment (PPE),

Relevant guidance
A long-lived asset (asset group) shall be tested for recoverability whenever events or changes in circumstances indicate that its carrying amount may not be recoverable [FAS 144R.8].

What impairment indicators should a pharmaceutical (or life science) entity consider?

Solution
Management of all entities should consider the general indicators given in paragraph 8 of FAS 144, when assessing whether there is an impairment of PPE. In addition, pharmaceutical entities should also consider industry-specific factors such as the following (not meant to be all-inclusive):

- Patent expiry date;
- Failure of the machinery to meet regulatory requirements;
- Technical obsolescence of the PPE (for example, because it cannot accommodate new market preferences);
- Market entrance of competitive products;
- Product recall and/or changes in the environment that makes the underlying product ineffective;
- Unfavourable court decision;
- Side-effects and related bad publicity;
- Relationship with other tangible and intangible assets; and
- Changes or anticipated changes in third-party reimbursement policies.
28. Treatment of validation batches

Background
A laboratory has just completed the development of a machine to mix components at a specified temperature to create a new formulation of aspirin. The laboratory produces several batches of the aspirin, using the new machinery to obtain validation (an approval for the use of the machine) from the relevant regulatory authorities. The validation of the machinery is a separate process from the regulatory approval of the new formulation of aspirin.

Relevant guidance
Property, plant, and equipment should be recorded at their historical cost which is the amount of cash, or its equivalent, paid to acquire an asset, which includes directly attributable expenditures incurred in acquiring the equipment and preparing it for use [CON 5 (para 67A)].

Should expenditure to validate machinery be capitalised?

Solution
The laboratory should capitalise the costs incurred (including materials, labour, applicable overhead) to obtain the necessary validation for the use of the machinery, together with the cost of the machinery. Validation is required to bring the machinery to its working condition. However, management should exclude abnormal validation costs caused by errors or miscalculations during the validation process or revalidation costs (such as wasted material, labour or other resources).
29. Carrying value of inventory

Background
Cerise carries a significant amount of inventory.

Relevant guidance
When there is evidence that the value of goods, in their disposal in the ordinary course of business, will be less than cost, whether due to physical deterioration, obsolescence, changes in price levels, or other causes, the difference should be recognised as a loss of the current period [ARB 43 Ch.4 St. 5-6].

What factors should management consider in order to assess whether the inventory is worth less than cost (lower cost or market)?

Solution
There are a number of general indications that management should consider when inventory for recovery. Pharmaceutical entities should also consider industry-specific factors such as the following:

- Patent expiry date;
- Inventory expiry date;
- Market entrance of similar products (e.g. generics);
- Changes in medical treatments;
- Advances in medicine;
- Product recalls; and
- Changes or anticipated changes in third-party reimbursement policies.
30. Treatment of development supplies

Background
A laboratory has purchased 10,000 batches of saline solution. These batches are used in trials on patients during various Phase 3 clinical tests. They can also be used for other testing purposes. Management is considering whether the batches should be recorded as an asset.

Relevant guidance
The costs of materials, whether from the enterprise’s normal inventory or acquired specially for research and development activities, that are acquired for research and development activities and have no alternative future uses (in research and development projects or otherwise) shall be expensed as incurred [FAS 2R. 11a].

An asset has three essential characteristics: (a) it embodies a probable future benefit that involves a capacity, singly or in combination with other assets, to contribute directly or indirectly to future net cash inflows, (b) a particular entity can obtain the benefit and control others’ access to it, and (c) the transaction or other event giving rise to the entity’s right to or control of the benefit has already occurred [FASB Concept Statement No. 6R. 26].

Solution
The batches do not meet the definition of inventory, but do meet the definition of an asset (other current asset or prepaid asset) since they have alternative future uses in other development projects. They should therefore be recorded at cost and accounted for as R&D expense as consumed in development.

Should costs associated with supplies used in clinical testing be accounted for as inventories?
31. Treatment of inventory of ‘in-development’ drugs

Background
Laboratory A has produced 15,000 doses of a new drug, following submission of the final filing for regulatory approval, so that it can go to market with the drug as soon as it gets scientific regulatory approval. The doses cannot be used for any other purpose. Management is considering whether the doses should be recorded as inventory.

Relevant guidance
The term inventory is used to designate the aggregate of those items of tangible personal property which:

(1) are held for sale in the ordinary course of business,
(2) are in process of production for such sale, or
(3) are to be currently consumed in the production of goods or services to be available for sale [ARB 43 Ch. 4 St. 1].

Assets are probable future economic benefits obtained or controlled by a company as a result of past transactions or events [Con 6R.25]

Solution
Laboratory A should capitalise the doses it has produced to the extent that they are recoverable. If final filing for regulatory approval indicates that marketing approval is probable, these items of inventory can be treated as fully recoverable (assuming the inventory will be sold and usable prior to expiration). An assessment of likelihood that regulatory approval will not be obtained should be made at each reporting period. If at any time regulatory approval is deemed to not be probable, the inventory should be written down to its net realisable value which is presumably zero assuming that the product cannot be sold.

How should the costs associated with the production of inventory for ‘in-development’ drugs be accounted for?
32. Treatment of inventory of ‘in-development’ generic drugs

Background
Tina Pharmaceuticals developed a generic version of an original drug whose patent is due to expire at the end of 20X3. Management believed the generic version was the chemical equivalent of the original drug and that economic benefits were probable.

Tina produced 15,000 doses of pre-launch inventory of the generic drug in June 20X3. The doses cannot be used for any other purposes. The patent on the original drug expired and marketing approval for the generic version was received in November 20X3. Management is considering whether the cost of the pre-launch inventory should be capitalised.

Relevant guidance
The term inventory is used to designate the aggregate of those items of tangible personal property which (1) are held for sale in the ordinary course of business, (2) are in process of production for such sale, or (3) are to be currently consumed in the production of goods or services to be available for sale [ARB 43 Ch. 4 St. 1].

Assets are probable future economic benefits obtained or controlled by a company as a result of past transactions or events [Con 6R.25]

Solution
Pre-launch inventory should be recorded as inventory at the lower of its cost or net realisable value. Management’s conclusion that the generic drug is the chemical equivalent of the original drug, and that economic benefits are probable, support the conclusion that such inventory is commercially viable. Accordingly, the pre-launch inventory costs are realisable (assuming the inventory will be sold and used prior to expiration). Approval for marketing was received before the end of the year, showing that the inventory has not been impaired. An assessment of likelihood that regulatory approval will not be obtained should be made at each reporting period. If at any time regulatory approval is deemed to not be probable, the inventory should be written down to its net realisable value which is presumably zero assuming that the product cannot be sold.
33. Advertising and promotional expenditure

Background
A company has developed a new drug that simplifies the long-term treatment of kidney disease. The company’s commercial department has incurred significant costs with a promotional campaign, including TV commercials and presentations in conferences and seminars for doctors.

Relevant guidance
The costs of advertising should be expensed either as incurred or the first time the advertising takes place except for direct response advertising or expenditures for advertising that are made subsequent to recognising revenues related to such costs [SOP 93-7R. 26].

How should these costs be accounted for?

Solution
The company should not recognise its advertising and promotional costs as an intangible asset, even though the expenditure incurred may provide future economic benefits; it should charge all promotional costs to the income statement as incurred or the first time the advertising takes place based on the policy it has selected pursuant to SOP 93-7.

The presentation of promotional costs in the income statement will depend on the analysis of expenses preferred by management (by nature or by function). Promotional costs should be classified as advertising and promotional costs if the analysis of expenses is presented by nature; however, more detailed analysis may be provided. Promotional costs should be included within marketing expenses if the analysis of expenses is presented by function.
34. Presentation of co-marketing expenses

Background

Gena and Himen have entered into a co-marketing agreement for a compound XY, developed by Himen, for a period of ten years. The agreement is material for both parties. Under the terms of the agreement, Gena has made an upfront payment and milestone payments based on the achievement of certain goals, such as receipt of approval from the regulatory authorities. In return, Himen has granted Gena exclusive marketing rights for XY in Japan.

Himen will manufacture the product and sell it to Gena at cost. Gena will also pay Himen 20% of its net sales of XY and will share a portion of any potential product liability. The promotion and commercialisation of drugs are Gena’s main activities, although in this case they are performed jointly with a third party.

Relevant guidance

A company should recognise revenue based on (a) the gross amount billed to a customer because it has earned revenue from the sale of the goods or services or (b) the net amount retained because it has earned a commission or fee depending on the relevant facts and circumstances [EITF 99-19R.6].

Solution

Gena’s accounting for its co-marketing expenditures will vary depending on its conclusion on whether it is the principal or agent in the arrangement based on the factors discussed in EITF 99-19. If Gena determines it is the principal in the Japan market, Gena should present the payments received from customers as sales revenue, and the cost of purchasing XY from Himen as inventory and then cost of goods sold. The co-marketing amounts paid to Himen of 20% of net sales of the product represents a royalty in return for the product rights in that territory and should be presented as cost of goods sold.

If Gena were to determine it was the agent in the Japan market, it would recognise revenue calculated as payments due from customers less payments owed to Himen.

How should Gena present its co-marketing expenditure in its financial statements?
35. Presentation of co-marketing income

Background
Gena and Himen have entered into a co-marketing agreement for a compound XY, developed by Himen, for a period of ten years. The agreement is material for both parties. Under the terms of the agreement, Gena has made an upfront payment and milestone payments based on the achievement of certain goals, such as receipt of approval from the regulatory authorities. In return, Himen has granted Gena exclusive marketing rights for XY in Japan.

Himen will manufacture the product and sell it to Gena at cost. Gena will also pay Himen 20% of its net sales of XY and will share a portion of any potential product liability. The promotion and commercialisation of drugs are Gena’s main activities, although in this case they are performed jointly with a third party.

Relevant guidance
A company should recognise revenue based on (a) the gross amount billed to a customer because it has earned revenue from the sale of the goods or services or (b) the net amount retained because it has earned a commission or fee depending on the relevant facts and circumstances [EITF 99-9R.6].

Revenue generally is realised or realisable and earned when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the seller’s price to the buyer is fixed or determinable; and collectibility is reasonably assured [SAB 104R.A1].

How should Himen present the co-marketing income it receives from Gena in its financial statements?

Solution
Himen would first need to allocate the revenue under the arrangement to the various revenue elements using the guidance in EITF 00-21. Himen’s accounting for its co-marketing income will then vary depending on its conclusion on whether it is the principal or agent in the arrangement based on the factors discussed in EITF 99-19. Assuming Himen determines that Gena is the principal for sales in Japan, Himen should recognise 100% of the sales of product XY to Gena as sales revenue and the corresponding costs of production as cost of sales. The co-marketing income, at 20% of Gena’s sales, should be presented as royalty income and disclosed separately as a component of revenue, if material.
Background
Arts Pharma markets a drug approved for use as a painkiller. Recent information shows the drug may also be effective in the treatment of cancer. Arts has commenced additional development procedures necessary to gain approval for this indication.

Relevant guidance
Research and development costs should be expensed when incurred [FAS 2R.12].

Should Arts capitalise any of the development costs?

Solution
Costs to perform research and development, including internal development costs, should be expensed as incurred regardless of past history with similar drugs or regulatory authority approval expectations.
37. Line extension development costs

**Background**

Degas Pharma owns a drug that has historically been approved for its pain-reducing effect on adults. Management now intends to obtain scientific approval to use the drug for the treatment of children. Degas has commenced additional development procedures necessary to gain approval for this line extension. Regulatory approval is needed for this line extension and the probability of obtaining approval is comparable to that of a new drug.

**Relevant guidance**

Research and development costs should be expensed when incurred [FAS 2R.12].

**Should Degas capitalise any of the development costs?**

**Solution**

Costs to perform research and development, including internal development costs, should be expensed as incurred regardless of past history with similar drugs or regulatory authority approval expectations.
38. Cost incurred for performance comparisons

Background
Van Gogh Ltd. has obtained regulatory approval for its new antidepressant drug and has started commercialisation. Van Gogh is now undertaking studies to verify the advantages of its drug over competing drugs already on the market. These studies will support Van Gogh’s sales efforts.

Relevant guidance
Research and development costs should be expensed when incurred [FAS 2R.12].

How should Van Gogh treat the costs incurred?

Solution
The expenditure incurred for studies to identify performance features should be expensed as incurred. This expense should be included in the appropriate income statement classification based on the nature of the expenditure. The studies are directed at providing marketing support and the nature of the amounts spent is that of a marketing expense.
39. Development costs for limited markets

Background
Da Vinci Pharma is currently developing a drug that will be used in the treatment of a very specific ailment affecting a small group of patients. Da Vinci has filed for initial regulatory approval.

Relevant guidance
Research and development costs should be expensed when incurred [FAS 2R.12].

Should Da Vinci capitalise any of the development costs?

Solution
Costs to perform research and development, including internal development costs, should be expensed as incurred regardless of past history with similar drugs or economic or regulatory authority approval expectations.
40. Cost-plus contract research arrangements

Background
Whistler Corp. enters into a contract research arrangement with Ruskin Inc. to perform research on the geometry of a library of molecules. Ruskin will catalogue the research results in a database.

Whistler will refund all of Ruskin’s direct costs incurred under the contract, plus paying a 25% premium on a quarterly basis as the work is completed.

Relevant guidance
An enterprise that incurs a liability to repay the other party(s) for research and development shall charge the research and development costs to expense as incurred [FAS 68R. 9]. The costs of services performed by others in connection with the research and development activities of an enterprise, including research and development conducted by others in behalf of the enterprise, shall be included in research and development costs [FAS 2R11.d].

Solution
Whistler should expense costs for the contract research (including the premium) as the costs are incurred by Ruskin. The activity is within the definition of research.

How should pharmaceutical entities account for contracted research arrangements?
41. Fixed-fee contract research arrangements

Background
Whistler Corp. enters into a contract research arrangement with Ruskin Inc. to perform research on the geometry of a library of molecules. Ruskin will catalogue the research results in a database.

Whistler will pay Ruskin LC3 million upon completion of the contracted work. The payment is based on delivery of the research services; there is no success-based contingency.

Relevant guidance
If the enterprise is obligated to repay any of the funds provided by the other parties regardless of the outcome of the research and development, the enterprise shall estimate and recognise that liability and record expense as incurred [FAS 68R. 5]. The costs of services performed by others in connection with the research and development activities of an enterprise, including research and development conducted by others in behalf of the enterprise, shall be included in research and development costs [FAS 2R11.d].

Solution
Whistler should accrue the contract research costs over the expected period of the research. The costs are expensed as Rusin performs the service and recorded as research expense. The activity is within the definition of research. The structuring of the payments does not alter the accounting treatment.

How should pharmaceutical entities account for contracted research arrangements?
42. Patent protection costs

Background
Velázquez Pharma has a registered patent on a currently marketed drug. Uccello Medicines Ltd. copies the drug’s active ingredient and sells the drug during the patent protection period. Velázquez goes to trial and is likely to win the case, but has to pay costs for its attorneys and other legal charges.

Should legal costs relating to the defence of pharmaceutical patents be capitalised?

Solution
The accounting treatment (i.e. capitalise or expense as incurred) would depend upon Velázquez’ policy for accounting for patent defence costs which should be consistently applied. Velázquez would not capitalise patent defence costs unless it believed it was probable the patent would be successfully defended and it could determine an evident increase in the value of the patent as a result of the defending the suit. In many cases, defence of a patent would maintain rather than increase the expected future economic benefits from the patent. Accordingly, patent defence costs would generally be expensed as incurred.

Relevant guidance
Assets are probable future economic benefits obtained or controlled by a particular entity as a result of past transactions or events [Con 6]. Legal and other costs of successfully defending a patent from infringement are ‘deferred legal costs’ only in the sense that they are part of the cost of retaining and obtaining the future economic benefit of the patent [Con 6R.247].

If defence of a patent lawsuit is successful, costs may be capitalised to the extent of an evident increase in the value of the patent. Legal costs which relate to an unsuccessful outcome should be expensed [AICPA TIS 2260R.03].
43. Accounting for research which results in a development candidate

Background
Sisley Pharma contracts with Wright Pharma to research possible candidates for further development in its anti-hypertension program. Sisley pays Wright on a cost-plus basis for the research, plus LC100,000 per development candidate which Sisley elects to pursue further. Sisley will own the rights to any such development candidates. After two years, Wright succeeds in confirming 10 candidates that will be used by Sisley.

Relevant guidance
Research and development costs should be expensed when incurred [FAS 2R.12].

How should payments for pharmaceutical research that subsequently becomes development be accounted for?

Solution
Costs to perform research and development should be expensed as incurred. Accordingly, Sisley’s payments relating to the cost-plus portion should be expensed as incurred and the additional costs relating to the successful development candidates (LC 200,000) should be expensed when it is probable Sisley will elect to pursue further.
44. Third-party development of own intellectual property

Background
Tiepolo Pharma has appointed Tintoretto Laboratories, a third party, to develop an existing compound owned by Tiepolo on its behalf. Tintoretto will act purely as a service provider without taking any risks during the development phase and will have no further involvement after regulatory approval. Tiepolo will retain full ownership of the compound. Tintoretto will not participate in any marketing and production arrangements. A milestone plan is included in the contract. Tiepolo agrees to make the following non-refundable payments to Tintoretto:

- LC2 million on signing the agreement
- LC3 million on successful completion of phase 2

Relevant guidance
Research and development costs should be expensed when incurred [FAS R.12].

Non-refundable advance payments for future research and development activities should be capitalised until the goods have been delivered or the related services have been performed. [EITF 07-03]

Solution
Tiepolo owns the compound and Tintoretto performs development on Tiepolo’s behalf. The initial upfront payment represents a prepayment for funding development by a third party which should be expensed as Tintoretto performs the research. Tiepolo should expense the milestone payment when it is probable the payment will be made.

How should pharmaceutical entities account for upfront payments and subsequent milestone payments in a long-term research and development (R&D) arrangement in which a third party develops their intellectual property?
45. Joint development of own intellectual property

Background

Tiepolo Pharma has appointed Tintoretto Laboratories, a third party, to develop an existing compound owned by Tiepolo on its behalf. The agreement effectively out-licenses Tiepolo’s compound to Tintoretto. Tiepolo and Tintoretto will set up a development steering committee to jointly perform the development and will participate in the funding of the development costs according to specific terms. Tiepolo agrees to make the following payments to Tintoretto:

- LCS 5 million on signing the agreement as an advance payment. Tintoretto has to refund the entire payment in the event of failure in development.
- 50% of total development costs on successful completion of phase 2 (after deducting the advance payment).
- In the case of successful completion of development and commercialisation, Tintoretto will receive milestone payments and royalty streams.

Relevant guidance

The costs of services performed by others in connection with the research and development activities of an enterprise, including research and development conducted by others in behalf of the enterprise, shall be included in research and development costs.[FAS R.11d].

To the extent that the financial risk associated with the research and development has been transferred because repayment of any of the funds provided by the other parties depends solely on the results of the research and development having future economic benefit, the enterprise shall account for its obligation as a contract to perform research and development for others [FAS 68R.10].

Non-refundable advance payments for future research and development activities should be capitalised until the goods have been delivered or the related services have been performed. [EITF 07-03]

Solution

Tintoretto becomes party to substantial risks in the development of Tiepolo’s compound, as it is only partly compensated for its development activities if the development succeeds (thereby buying into the potential success of the future product). Tiepolo effectively reduces its exposure to ongoing development costs and to potential failure of the development of its compound. The payments represent advance funding for future (in the case of the upfront payment) and past (for milestone payment) development of its own intellectual property by a third party. Therefore, the advance payment should be initially capitalised as a prepaid service asset and expensed over the development period commencing when successful development of the compound is probable. The milestone payment should be expensed over the Phase 2 development period commencing when successful completion of Phase 2 is probable.

Tiepolo should consider whether Tintoretto has the financial wherewithal to repay the advance payment if the development is unsuccessful. If Tintoretto does not have the ability to repay the advance if the drug is not successful or collectibility is otherwise uncertain, Tiepolo should amortise the advance payment and milestone over the development period.
6. External development of own intellectual property with buy-back options

Background
Tiepolo Pharma has appointed Tintoretto Laboratories, an independent, financially robust third party, to develop an existing compound owned by Tiepolo on its behalf. The agreement effectively out-licenses Tiepolo’s compound to Tintoretto. Tiepolo will neither retain any involvement in the development of its compound nor participate in the funding of the development. However, in the case of successful completion of the development as evidenced by final submission of relevant documents for regulatory approval in the key markets, Tiepolo has the option to buy back the right of commercialisation of its compound. The following terms are agreed:

- If the development fails, Tintoretto bears all the costs it incurred without any compensation.
- If the development is successful and Tiepolo exercises its buy-back-option, Tintoretto receives an agreed buy-back payment (as well as future milestone payments and royalty streams).
- If the development is successful and Tiepolo does not exercise the option, Tintoretto can commercialise the compound on its own (paying milestones and royalties to Tiepolo under the license arrangement).

Relevant guidance
If an enterprise is obligated to repay any of the funds provided by other parties regardless of the outcome of the research and development, the enterprise shall estimate and recognise that liability. To conclude that a liability does not exist, the transfer of the financial risk involved with the research and development from the enterprise must be substantive and genuine [FAS 68R.5 and R.6]. The following are examples of conditions leading to the presumption that an enterprise will repay the other parties [FAS 68R.8]:

- The enterprise has indicated an intent to repay all or a portion of the funds provided regardless of the outcome of the research and development.
- The enterprise would suffer a severe economic penalty if it failed to repay any of the funds provided to it regardless of the outcome of the research and development.
- A significant related party relationship exists between the enterprise and the parties funding the research and development at the time the enterprise enters into the arrangement.
- The enterprise has essentially completed the project before entering the arrangement.
- If the enterprises obligation is to perform research and development for others and the enterprise subsequently decides to exercise an option to purchase the other parties’ interests in the research and development arrangement or to obtain the exclusive rights to the results of the research and development, the nature of those results and their future use shall determine the accounting for the purchase transaction [FAS 68R.11].
- The costs of services performed by others in connection with the research and development activities of an enterprise, including research and development conducted by others in behalf of the enterprise, shall be included in research and development costs [FAS 2.11d].

Solution
Tintoretto takes all risks in the development of Tiepolo’s compound, being compensated only for its development activities in the case of success (thereby buying itself into the potential success of the future product). Tiepolo effectively removes its exposure to failure of the development of its compound, having transferred all development risks to Tintoretto. By paying the agreed buy-back option, Tiepolo reacquires the commercialisation right intangible asset; however, since the payment is triggered upon filing for regulatory approval Tiepolo would expense the payment as research and development. If Tiepolo were to make the payment when regulatory approval of the project is received, the buyback payments and future milestone payments would be capitalised when paid (or when probable in the case of the milestone payments) and then amortised over the useful life of the commercialisation right.

Tintoretto should consider whether the counterparty in similar arrangements would be variable interest entities for which it would need to consider whether it would be required to consolidate the entity under FIN 46.
47. Collaboration agreement to develop a drug – separable arrangements

Background

Sargent and Chagall enter into a collaboration deal in which Sargent will pay Chagall for developing and manufacturing a new antibiotic originally discovered by Chagall. Sargent will have exclusive marketing rights to the antibiotic if it is approved. The contract terms require the following payments:

- Upfront payment of LC5 million on signing of the contract;
- Milestone payment of LC5 million on filing for stage 3 clinical trial approval;
- Milestone payment of LC7 million on securing final regulatory approval; and
- LC11.5 per unit, which equals the estimated cost plus 15%, once commercial production begins.

The cost-plus 15% is consistent with Sargent’s other recently negotiated supply arrangements for drugs with comparable manufacturing complexity.

Relevant guidance

The costs of services performed by others in connection with the research and development activities of an enterprise, including research and development conducted by others in behalf of the enterprise, shall be included in research and development costs which shall be charged to expense as incurred [FAS 2R.11d and R.12].

Solution

The terms for product supply at cost plus 15% are consistent with Sargent’s other supply arrangements which is assumed to represent fair value. As the antibiotic is still under development, the upfront payment should be expensed upon signing of the contract and the first milestone payment should be expensed when it is probable that the payment will be made. As the second milestone payment will only be paid upon securing final regulatory approval, this payment should be capitalised and amortised over the estimated useful life of the antibiotic.

If the contract terms did not represent fair value, the payments would have to be allocated to the development and production supply components of the arrangement using fair value as the allocation key. Sargent should also consider whether the manufacturing arrangement is separable under EITF 00-21. If Sargent is the only party which is capable of producing the product then the manufacturing agreement may not be separable from the development elements and the upfront and milestone payments may need to be recognised over the estimated term of the arrangement, including the follow-on manufacturing period.
Background

Buonarroti entered into a competitive bidding arrangement to acquire a patent. Buonarroti won the bidding with a final offer of LC0 million, which it agrees to settle in exchange for 5% of its publicly listed shares. When the purchase is made public, but before the date of exchange, the shares drop by 50% to a value of LC5 million. Buonarroti must recognise the patent in its balance sheet.

Relevant guidance

For equity instruments exchanged for the receipt of goods or services from a non-employee, an issuer should measure the fair value of the equity instruments using the stock price and other measurement assumptions as of the earlier of either of the following:

(a) The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a “performance commitment”); or

(b) The date at which the counterparty’s performance is complete.

A performance commitment is a commitment under which performance by the counterparty to earn the equity instruments is probable because of sufficiently large disincentives for non-performance. The ability to sue for non-performance, in and of itself, does not represent a sufficiently large disincentive to ensure that performance is probable [EITF 96-8 Issue 1].

The cost of a non-monetary asset exchanged for another nonmonetary asset is the fair value of the asset surrendered to obtain it unless the fair value of the asset received is more clearly evident. [APB 29 R.18].

Solution

Buonarroti should record the transaction based on the value of the consideration (i.e. listed shares) given up since its fair value is more readily determinable. Buonarroti would need to assess whether sufficiently large disincentives for non-performance existed to make the exchange of the patent probable. Generally, it would be rare that such a disincentive would exist for purposes of applying EITF 96-18. Accordingly, Buonarroti would record the patent based on the fair value of the shares given up on the exchange date. Assuming the announcement date in this scenario is also the exchange date, Buonarroti would record the patent at LC 5 million.

The conclusion to capitalise or expense the cost of the payment will be based on whether or not the patent has alternative future uses in research and development projects or otherwise.
49. Accounting for acquired early-stage projects

Background

Picasso Pharma has acquired a new drug compound, which is currently in phase I clinical development. Picasso has capitalised the costs for acquiring the new drug compound as an intangible asset. Subsequently, Picasso’s scientists detect that the new drug substance is much more effective when used in a combination therapy with another drug. Management stops the current development activities for the new drug. New phase I clinical trials are started for the combination therapy.

Relevant guidance

Research and development costs should be expensed when incurred [FAS 2R.12].

Solution

Not Applicable - Intangible assets cannot be capitalised for unapproved product compounds under US GAAP.
50. Cost of collaboration arrangements

**Background**

Pollock Corp. and Vermeer enter into a collaboration arrangement. Pollock receives an upfront payment for an anti-infective product currently in development and subsequent milestone payments. Vermeer will receive the right to sell the product and will pay Pollock a royalty share. The cost to market the product is borne by Vermeer.

**Relevant guidance**

The costs of services performed by others in connection with the research and development activities of an enterprise, including research and development conducted by others in behalf of the enterprise, shall be included in research and development costs [FAS 2R.11d].

**How should the costs of collaboration agreements be accounted for?**

**Solution**

Vermeer should expense the upfront payment upon execution of the agreement. The accounting for the milestones will depend on whether the milestones occur prior to or after regulatory approval. Pre-approval milestone payments should be expensed when it is probable that the payment will be made. Post-approval milestones would be capitalised and amortised over the life of the anti-effective product.

Royalty payments to Pollock made after completion of the development should be recognised by Vermeer as the sales of the drug are recognised (generally as cost of sales).
51. Production technology development expenditure

Background
Gauguin SA is developing a technology to enable production of its new bio-pharmaceutical vaccine. The technology to produce the vaccine will require FDA approval and has no alternative use. Gauguin incurs both technology development costs and validation costs leading up to the approval.

Relevant guidance
Engineering activity required to advance the design of a product to the point that it meets specific functional and economic requirements and is ready for manufacture is an example of an activity that typically would be included in research and development activities [FAS R.9].

Costs of materials, equipment or facilities that are acquired or constructed for a particular research and development project and that have no alternative future uses (in other research and development projects or otherwise) and research and development costs at the time the costs are incurred [FAS 2R.11a]. Research and development costs shall be expensed when incurred [FAS 2R.12].

Solution
Because the technology requires FDA approval and has no alternative use, Gauguin should expense the development and validation costs relating to the new technology as incurred. In practice, facilities or equipment would generally be considered to have alternative future use and would therefore be capitalised.

Before any inventory produced using a new production method can be sold, relevant regulatory authorities must approve the production process. How should pharmaceutical entities account for validation expenditures?
Background
Monet Pharma acquires the marketing rights in certain territories for an AIDS product developed by Renoir. The collaboration includes the following terms:

- Upfront payment of LC20 million on signing of the contract
- No milestone payments
- Supply of the product at LC80 per unit, where the estimated cost per unit is LC100

Relevant guidance
An intangible asset that is acquired either individually or with a group of other assets (but not those acquired in a business combination) shall be initially recognised and measured based on its fair value. [FAS 142.R9]

Solution
Assuming Monet acquired the rights to an approved AIDS product, Monet’s management has to assess whether the agreed terms reflect the fair value of the components of this arrangement. In this case, the supply price does not cover the estimated costs, so the agreed amounts do not reflect fair value of the supply price. Therefore, Monet should estimate the fair values for the two components of the agreement. The fair value of product supply can be estimated at cost plus a profit margin consistent with the manufacturing complexity inherent in production of the drug. This should be multiplied by the expected supply amounts and a separate inventory prepayment should be recorded separately from the acquired marketing rights. The remaining upfront payment should be capitalised as a marketing intangible by Monet.

How should pharmaceutical entities account for collaboration agreements that contain several components?
53. Development loan – market terms

Background
Warhol Inc. lends LC1 million to Lichtenstein Inc., a small biotech entity, for development of a new active substance. The loan agreement contains the usual market conditions for unsecured loans and has to be paid back in five years. Lichtenstein has no material sources of cash in-flows other than those resulting from successful development of the substance. Warhol has no other relationships with Lichtenstein.

Relevant guidance
If repayment to the enterprise of any loan or advance by the enterprise to the other parties depends solely on the results of the research and development having future economic benefit, the loan or advance shall be accounted for as costs incurred by the enterprise [FAS 68R].

Non-refundable advance payments for future research and development activities should be capitalised until the goods have been delivered or the related services have been performed. [EITF 07-03]

How should a lender account for development loans?

Solution
The repayment of the loan is not probable since the payment of the loan depends on cash flows that will result from successful development of the substance. In addition, Lichtenstein is not performing services for Warhol which could be analogised to as a non-refundable advance payment and initially capitalised as a prepaid asset and recognised as research and development expense as Lichtenstein performs research on the substance. Warhol should recognise the originated loan as an expense when made and recognise the recovery of the loan when it is reasonably assured of collection, which generally would be when the cash is received.

Additionally, Warhol should evaluate whether it would be the primary beneficiary of Lichtenstein, Inc. pursuant to FIN 46. If so, Lichtenstein should be consolidated in Warhol’s financial statements, causing the intercompany loan to be expensed as development as it is consumed, rather than as described above.
54. Development loan – below market terms

Background

Warhol Inc. lends LC10 million to Lichtenstein Inc., a small biotech entity, for development of Lichtenstein’s new active substance. The loan agreement transfers the substance’s marketing rights in certain territories to Warhol upon successful development. No interest is charged on the loan. Lichtenstein has no material sources of cash in-flows other than those resulting from successful development of the substance.

Relevant guidance

If repayment to the enterprise of any loan or advance by the enterprise to the other parties depends solely on the results of the research and development having future economic benefit, the loan or advance shall be accounted for as costs incurred by the enterprise. [FAS 68R.12]

The costs of intangible assets that are purchased from others for use in research and development activities and that have alternative future uses (in research and development projects or otherwise) shall be accounted for in accordance with FASB Statement No. 142, Goodwill and Other Intangible Assets. The amortisation of those intangible assets used in research and development activities is a research and development cost. However, the costs of intangibles that are purchased from others for a particular research and development project and that have no alternative future uses (in other research and development projects or otherwise) and therefore no separate economic values are research and development costs at the time the costs are incurred. [FAS R.1c].

Non-refundable advance payments for future research and development activities should be capitalised until the goods have been delivered or the related services have been performed. [EITF 07-03]

Solution

Warhol should evaluate first whether Liechtenstein Inc. would represent a VIE, pursuant to FIN 46(R), and whether it would be the primary beneficiary of the VIE. If so, Lichtenstein should be consolidated in Warhol’s financial statements, causing the intercompany loan to be expensed as development as it is consumed.

Assuming that Liechtenstein is not a VIE requiring consolidation by Warhol, Warhol should allocate the LC 10 million payment between the rights obtained in acquiring the substances marketing rights and the loan based on the fair value of the marketing rights. The substance is not yet approved so the amount allocated to the marketing rights would be expensed as development costs. The repayment of the loan is not probable since the payment of the loan depends on cash flows that will result from successful development of the substance. Therefore, the loan would be initially capitalised as a non-refundable advance payment and recognised as research and development expense as Lichtenstein performs research on the substance. Warhol should recognise the originated loan as a recovery of incurred research and development costs when it is reasonably assured of collection, which generally would be when the cash is received.
55. Sales target milestone with fair royalty

Background
Rembrandt Pharmaceuticals acquired the rights to sell an anti-obesity drug in the United Kingdom from Watteau Ltd. through a development agreement. The development agreement required Rembrandt to make several milestone payments to Watteau, including a LC25 million payment if cumulative sales of the anti-obesity drug reach LC250 million. A royalty payment schedule is also included in the agreement. The royalty payment rate represents fair value relative to comparable in-licensing arrangements.

Upon filing for regulatory approval, Rembrandt projects lifetime sales of the drug in the UK to be over LC500 million.

Relevant guidance
An estimated loss from a contingency shall be accrued by a charge to income of both of the following conditions are met:

a. Information indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements.

b. The amount of loss can be reasonably estimated.

How should pharmaceutical entities account for milestone payments based upon the achievements of sales targets?

Solution
Because the agreement includes a market-rate royalty payment, the sales milestone is additional consideration for acquiring the product commercialisation rights and the payment should be accounted for as an increase to the product rights intangible asset. The entire sales target milestone must be accrued as a provision once achievement of the target is probable and the payment will be required to be made. Based upon Rembrandt’s sales forecasts, probability may be achieved upon obtaining regulatory approval.

Consideration must be given as to whether the contractual payments represent fair value. If the relative weighting of the milestone payments indicates fair values that are clearly different from the actual payments, they should be allocated in accordance with that fair value weighting. Other factors to consider in determining whether the milestone represents contingent consideration or additional royalty include the frequency of milestone payments and the effective annual royalty rates over the term of the agreement (i.e. does the milestone represent a catch-up of past royalties).
56. Annual sales target milestone with fair royalty

**Background**
Rembrandt Pharmaceuticals acquired the rights to sell an anti-obesity drug in the United Kingdom from Watteau Ltd. through a development agreement. The development agreement required Rembrandt to make several milestone payments to Watteau, including a LC5 million payment in any year that annual sales of the anti-obesity drug reach LC100 million. A royalty payment schedule is also included in the agreement. The royalty payment rate represents fair value relative to comparable in-licensing arrangements.

Upon filing for regulatory approval, Rembrandt forecasts that the lifetime sales of the drug in the UK will be more than LC500 million over the remaining 10-year patent life. The sales are expected to develop quickly after launch, and taper and then decline rateably with the introduction of me-too drugs. Based upon its forecasts at launch, Rembrandt’s achievement of sales in excess of LC100 million in any year is considered unlikely.

**Relevant guidance**
An estimated loss from a contingency shall be accrued by a charge to income of both of the following conditions are met:

a. Information indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements.

b. The amount of loss can be reasonably estimated.

**Solution**
Because the agreement includes a market-rate royalty payment, the sales milestone is additional consideration for acquiring the product commercialisation rights and the payment should be accounted for as an increase to the product rights intangible asset. The entire sales target milestone must be accrued as a provision once achievement of the target is probable and the payment will be required to be made. Given that Rembrandt’s forecasts consider it unlikely annual sales will reach LC 100 million, no accrual would be necessary. Rembrandt should continuously evaluate its product sales forecasts and accrue the payment if it were to become probable of being made.

Consideration must be given as to whether the contractual payments represent fair value. If the relative weighting of the milestone payments indicates fair values that are clearly different from the actual payments, they should be allocated in accordance with that fair value weighting. Other factors to consider in determining whether the milestone represents contingent consideration or additional royalty include the frequency of milestone payments and the effective annual royalty rates over the term of the agreement (i.e. does the milestone represent a catch-up of past royalties).
57. Sales target milestone with below-market royalty

Background

Rembrandt Pharmaceuticals acquired the rights to sell an anti-obesity drug in the United Kingdom from Watteau Ltd. through a development agreement. The development agreement required Rembrandt to make several milestone payments to Watteau, including a LC25 million payment if cumulative sales of the anti-obesity drug reached LC250 million. While a royalty payment schedule is included in the agreement, the royalty payment rate is less than comparable in-licensing arrangements.

Upon filing for regulatory approval, Rembrandt projects that the lifetime sales of the drug in the UK will be over LC500 million.

Relevant guidance

An estimated loss from a contingency shall be accrued by a charge to income of both of the following conditions are met:

a. Information indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements.

b. The amount of loss can be reasonably estimated.

Solution

The milestone serves as a proxy for sales royalties in this arrangement, as the sales royalty payments required by the arrangement are less than fair value. The milestone accrual should be recorded as a royalty expense if the income statement is presented by nature of expenses, or as cost of goods sold if presented by function.

As the sales milestone represents a royalty, sales of the product is the past event that would require its accrual. Once Rembrandt begins selling the drug, the forecast sales milestone should be accrued rateably over the initial LC250 million in sales, as Rembrandt expects to exceed the milestone target level.

Consideration must be given as to whether the contractual payments represent fair value. If the relative weighting of the milestone payments indicates fair values clearly different from the actual payments, they should be allocated in accordance with that fair value weighting.
58. Sales target milestone with no royalty

**Background**

Rembrandt Pharmaceuticals acquired the rights to sell an anti-obesity drug in the United Kingdom from Watteau Ltd. through a development agreement. The development agreement required Rembrandt to make several milestone payments to Watteau, including a LC5 million payment if cumulative sales of the anti-obesity drug reached LC250 million. Contrary to other similar product acquisitions, the agreement does not require any royalty payments. Otherwise, each milestone payment represents fair value relative to the stage of development or marketing, based upon comparable in-licensing arrangements.

Upon filing for regulatory approval, Watteau forecasts that the lifetime sales of the drug in the UK will be over LC500 million.

**Relevant guidance**

Revenue should be recognised when realised or realisable and earned when all of the following criteria are met [SAB Topic R.A1]:

- Persuasive evidence of an arrangement exists
- Delivery has occurred or services have been rendered
- The seller’s price to the buyer is fixed or determinable
- Collectibility is reasonably assured

Contingent income “accrues” when the changes in the factor(s) on which the contingent payment is based actually occur [SAB Topic 13 A.4c]

**Solution**

Watteau should record the sales milestone receipt as revenue, once it is earned and its collection is reasonably assured. Accordingly, the sales milestone should be accrued only once cumulative sales reach LC250 million.

Consideration must be given as to whether the contractual payments represent fair value and account for the payments related to each deliverable in accordance with the guidance in EITF 00-21.
59. Abnormal validation costs

Background
Delacroix SA scrapped the first validation batch produced by its new plant because insufficient measurements were recorded. The subsequent batch included all required measurements and was used to successfully validate the plant with the regulatory authorities.

Relevant guidance
Abnormal costs of idle facility expense, freight, handling costs, and waste materials (spoilage) should be recognised as current period charges. [FAS 151R.1]

How should pharmaceutical and life sciences entities account for abnormal validation costs?

Solution
Since the background refers to the validation of a new plant, this assumes that regulatory approval for the underlying product has already been obtained.

Delacroix SA must expense the first validation batch as waste material/spoilage. However, the costs of the subsequent batch should be capitalised in the costs of inventory (if sellable) or equipment as a cost to ready the asset for its intended use (if not sellable).
60. Impairment of development costs prior to use

Background
Dali Pharmaceuticals has capitalised external development costs as an intangible asset relating to a compound that has not been approved. Subsequently, Dali identified side effects associated with the compound that indicate its value is severely diminished and an impairment charge must be recognised.

Relevant guidance
Research and development costs should be expensed when incurred [FAS 2R.12].

Where should pharmaceutical entities classify impairment charges on development intangible assets before such assets are available for use?

Solution
Development costs would not be capitalised under US GAAP.
61. Impairment of development costs after regulatory approval

Background
Dali Pharmaceuticals has capitalised development costs as an intangible asset relating to a drug that has been approved and is being marketed. Competitive pricing pressure from the early introduction of generic drugs causes Dali to recognise an impairment of the intangible asset.

Relevant guidance
Research and development costs should be expensed when incurred [FAS 2R.12].

Where should pharmaceutical entities classify impairment charges on development intangible assets which are currently marketed?

Solution
Development costs would not be capitalised under US GAAP; however, impairment charges relating to intangible assets for approved products would be classified in the same line as the related amortisation was recorded, generally as cost of sales.
62. Single market impairment accounting

Background
By way of a collaboration agreement, Veronese SpA acquired the rights to market a topical fungicide cream in the Eastern Hemisphere. The acquired rights apply broadly to the entire territory. For unknown reasons, patients in Greece prove far more likely to develop blisters from use of the cream, causing Veronese to withdraw the product from that country. As fungicide sales in Greece were not expected to be significant, loss of the territory, taken in isolation, does not cause the overall net present value from sales of the drug to be less than its carrying value.

Relevant guidance
An amortisable long-lived asset (asset group) shall be tested for recoverability whenever events or changes in circumstances indicate that its carrying amount may not be recoverable [FAS 144.R8c]. The carrying amount of a long-lived asset (asset group) is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset (asset group) [FAS 144R.7].

Long-lived assets shall be grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities [FAS 144R.10].

How should pharmaceutical companies account for the rescission of a drug’s marketing approval in a specific territory?

Solution
Veronese acquired the rights to market the fungicide cream over a broad territory and not specifically to Greece; therefore, the entire territory would likely be determined to be the lowest level of identifiable cash flows for testing impairment of the marketing rights. Because Greece was not expected to be significant, the withdrawal of the product from the Greece market would not be considered a triggering event requiring an impairment analysis to be performed.

However, Veronese’s management should carefully consider whether the blistering in one jurisdiction is indicative of potential problems in other territories. If the issue cannot be isolated, a triggering event would be considered to have occurred and a broader impairment analysis should be performed, including the potential for more wide-ranging sales losses. Note that under US GAAP, impairment testing for amortisable assets is performed in two steps. First the undiscounted future cash flows would be compared to the carrying value of the asset. If the carrying value exceeded the undiscounted future cash flows, the carrying value is then compared to the fair value of the asset and an impairment charge would be recognised for the shortfall.
63. Impairment of an acquired early-stage project

Background
Seurat Pharmaceutical has acquired a new drug compound, which is currently in phase I clinical development. Seurat has capitalised the costs for acquiring the drug as an intangible asset. Soon after acquisition of the drug, the results of the phase I clinical trials show that the drug is not likely to be effective for the intended therapy. Management terminates development of the drug.

Seurat’s scientists will use technology directly related to the acquired intangible in developing one of Seurat’s other drugs.

Relevant guidance
Research and development costs should be expensed when incurred [FAS 2R.12].

How should a pharmaceutical entity amortise an intangible asset related to an acquired early-stage project when utilising the results for development of a drug other than the drug for which the project was originally acquired?

Solution
Development costs would be expensed under US GAAP.
64. Reversals of impairment losses (cost model)

Background
Rubens Corp. markets a weight-loss drug for which development costs have been capitalised. A competing drug was launched on the market with much lower pricing. Rubens recorded an impairment of the capitalised development intangible asset due to a reduction in the amounts it estimated that it could recover as a result of this rival drug. Subsequently, the competing drug was removed from the market because of safety concerns. The market share and forecast cash flows generated by Ruben’s drug significantly increased.

Relevant guidance
If an impairment loss is recognised, the adjusted carrying amount of a long-lived asset shall be its new cost basis. Restoration of a previously recognised impairment loss is prohibited [FAS 144R.15].

How should pharmaceutical entities account for reversals of impairment losses for intangible assets accounted for under the cost model?

Solution
Development costs would not be capitalised under US GAAP; however, if an intangible asset had been recorded for an approved product, Rubens would not restore the previously recognised impairment loss as the prior write-down is deemed to have created a new cost basis for the asset which can not be written back up.
65. Impairment testing and useful life

Background
Fra Angelico Inc. has a major production line that produces its blockbuster antidepressant. The production line has no alternative use. A competitor launches a new antidepressant with better efficacy. Angelico expects sales of its drug to drop quickly and significantly. Although positive margins are forecast to continue, management identifies this as an indicator of impairment. Management may exit the market for this drug earlier than previously contemplated.

How should pharmaceutical entities assess the impairment and useful lives of long-lived assets where impairment indicators have been identified?

Solution
Assuming that the antidepressant asset group represents the lowest level of identifiable cash flows, Fra Angelico should evaluate the carrying amount of the antidepressant’s asset group (including the production line) relative to its future undiscounted cash flows. An impairment loss should be recognised if the carrying amount of the antidepressant’s asset group (including the production line) exceeds the future undiscounted cash flows. The resultant impairment would be based on the difference between the carrying amount of the unit and its fair value.

In addition, when the Fra Angelico should also revise the estimated useful life for the affected assets remaining after the impairment analysis is performed based on the estimated period it expects to obtain economic benefit from the unit.
66. Amortisation method of development intangible assets

Background
Raphael & Co. has begun commercial production and marketing of an approved product. Development costs for this product were capitalised in accordance with the criteria specified in IAS 38R. The patent underlying the new product will expire in 10 years.

Relevant guidance
Research and development costs should be expensed when incurred [FAS 2R.12].

Once a drug is being used as intended, what is the appropriate method of amortising the capitalised development costs?

Solution
Development costs would not be capitalised under US GAAP.
67. Amortisation life of development intangible assets

Background
Raphael & Co. has begun commercial production and marketing of an approved product. Development costs for this product were capitalised in accordance with the criteria specified in IAS 38R. The patent underlying the new product will expire in 10 years; however, Raphael’s business plan is to use the compound in an over-the-counter drug after nine years to establish market presence. The business plan indicates a further economic useful life for the compound of 10 years after patent expiry and supports attribution of the intangible cost to the patent and compound.

Relevant guidance
Research and development costs should be expensed when incurred [FAS 2R.12].

Once a drug is being used as intended, what is the appropriate method of amortising the capitalised development costs?

Solution
Development costs would not be capitalised under US GAAP; however, if an intangible asset had been recorded for an approved product, Raphael should consider the criteria in Solution 6 for determining the useful life of the asset, paying particular attention to the period over which the economic benefits from the product are substantially received.
68. Presentation of capitalised development costs

Background
Dali Pharmaceuticals capitalised the development costs relating to a diabetes drug that has been approved and is being marketed as an intangible asset. Amortisation of the development costs is being recorded on a straight-line basis over the remaining patent life.

Relevant guidance
Research and development costs should be expensed when incurred [FAS 2R.12].

Where should the amortisation of development costs be classified in a pharmaceutical entity’s income statement?

Solution
Development costs would not be capitalised under US GAAP; however, if an intangible asset had been recorded for an approved product, amortisation expense would generally be classified within cost of sales.
69. Recognition of raw materials as inventory until a decision is made about its usage

Background

Altdorfer Pharma Corp. buys bulk materials used for manufacturing a variety of drugs. The material is used for marketed drugs, samples and drugs in development. The material is warehoused in a common facility and is released to production based upon orders from the manufacturing and development departments.

Relevant guidance

Inventories are items of tangible personal property which are:

1. held for sale in the ordinary course of business,
2. are in process of production for such sale, or
3. are to be currently consumed in the production of goods or services to be available for sale [ARB 43.Ch.4.Stmt. 1].

The costs of materials, whether from the enterprise’s normal inventory or acquired specially for research and development activities, that are acquired for research and development activities and have no alternative future uses (in research and development projects or otherwise) shall be expensed as incurred [FAS 2R. 11a].

Solution

Management should initially recognise the bulk materials as inventory. The costs would remain capitalised if used in the manufacture of other drugs or would be expensed as either research and development expense or marketing expenses if used in development or as samples, respectively.
70. Pre-launch inventory produced before filing

Background

Van Eyck Ltd. has an asthma drug in development. Management believes there is a 0% likelihood that development will succeed and filing for final regulatory approval will occur in the near term. Although approval is not yet probable, Van Eyck takes the risk of building inventories of the finished product in order to facilitate immediate launch after regulatory approval. The inventory has no alternative use.

The inventory building begins with small production runs prior to filing for final regulatory approval and continues after the filing.

Relevant guidance

Assets are probable future economic benefits obtained or controlled by a company as a result of past transactions or events [CON 6 R.25].

Inventories are assets [ARB 43.4 (st1)]:

(1) held for sale in the ordinary course of business
(2) in the process of production for such sale; or
(3) currently consumed in the production of goods or services to be available for sale.

The primary basis of accounting for inventories is cost. Cost is understood to mean acquisition and production cost. [ARB 43.4 (st 3)].

The measurement of such losses is accomplished by applying the rule of pricing inventories at cost or market, whichever is lower. [ARB 43.4 (st 5)]

A write-down of inventory creates a new cost basis that subsequently cannot be marked up based on changes in underlying circumstances. [SAB topic 5 BB, ARB 43 (fn 2)]

Solution

Van Eyck’s management does not believe the asthma drug has achieved technological feasibility prior to filing for final regulatory approval. Therefore, inventory manufactured prior to this filing is immediately written down to zero because it is not probable that future economic benefits will be obtained from the inventory. The write-down should be recorded in as research and development expense.

Once Van Eyck has demonstrated that future economic benefits will be obtained and technological feasibility had been reached, inventory costs should be capitalised and carried at its lower of cost or market value, subject to net realisable value testing. The write-down recorded prior to this revised assessment should not be reversed.

What is the carrying amount of pre-launch inventory?
71. Net costs of validation batches sold

Background
Durer Pharma produces sample products for validation of a new oncology production line at a cost of LC100,000. Durer receives regulatory approval for the production line based upon the sample production run and plans to sell the validation batch for LC75,000.

Relevant guidance
Property, plant, and equipment should be recorded at their historical cost which is the amount of cash, or its equivalent, paid to acquire an asset, which includes directly attributable expenditures incurred in acquiring the equipment and preparing it for use [CON 5 (para 67A)].

How should pharmaceutical entities treat costs to produce product used to validate a plant if the product can subsequently be sold?

Solution
Durer Pharma should capitalise the LC25,000 net cost of the validation batch (cost of LC100,000 less net selling price of validation batch of LC75,000) as PPE. The remaining LC75,000 should be capitalised as inventory. The incremental cost over the revenue received would be considered costs incurred to ready the asset for its intended use. Other reasonable methods of allocating the costs between the inventory and validation may also be available for use.
72. Net gain on sale of validation batches sold

**Background**
Durer Pharma produces sample products for validation of a new oncology production line at a cost of LC100,000. Based upon the sample production run, Durer receives regulatory approval for the production line and plans to sell the validation batch for LC150,000.

**Relevant guidance**
Property, plant, and equipment should be recorded at their historical cost which is the amount of cash, or its equivalent, paid to acquire an asset, which includes directly attributable expenditures incurred in acquiring the equipment and preparing it for use [CON 5 (para 67A)].

**How should pharmaceutical entities treat costs to produce product used to validate a plant if the product can subsequently be sold?**

**Solution**
Durer should capitalise the inventory as LC 100,000. When the validation batches are commercially sold, Durer should recognise the gross sales (LC 150,000) and costs (LC 100,000) as there was no incremental cost in the production of the validation batches that would increase the cost of the equipment.
Background
Caravaggio Corp.’s leading product is a vaccine. The vaccine’s antibody is produced using virus cultures. These cultures and the resulting antibody are an important part of Caravaggio’s total inventory costs.

Relevant guidance
Inventories are assets [ARB 43.4 (st1)]:
(1) held for sale in the ordinary course of business
(2) in the process of production for such sale; or
(3) currently consumed in the production of goods or services to be available for sale.

The primary basis of accounting for inventories is cost. Cost is understood to mean acquisition and production cost. [ARB 43.4 (st3)]

Should vaccine cultures used in the production of pharmaceutical products be measured at cost or at fair value less cost to sell?

Solution
Caravaggio should account for its production of vaccine cultures at cost as a component of inventories.
Regal and Simba enter into an agreement in which Regal will license Simba’s know-how and technology to manufacture a compound for AIDS. Regal will use Simba’s technology in its facilities for a period of three years. Simba will have to keep the technology updated and in accordance with Regal’s requirements only during this three-year period. Simba obtains a non-refundable upfront payment of LC3 million for access to the technology. Simba will also receive a royalty of 20% from sales of the AIDS compound, if Regal successfully develops a marketable drug.

The 20% royalty is in line with other comparable royalty arrangements entered into by Regal.

Relevant guidance

When the elements of an out-licensing arrangement qualify as single units of accounting under EITF 00-21, the upfront fee should be deferred over the contractual life of the arrangement unless the upfront payment is in exchange for a product, service or right and represents the culmination of a separate earnings process [SAB 104]. Revenue should be recognized on a straight-line basis, unless evidence suggests that the revenue is earned or obligations are fulfilled in a different pattern, over the contractual term of the arrangement or the expected period, during which those specified services will be performed, whichever is longer [SAB 104].

If a multiple-element software arrangement includes explicit or implicit rights to post-contract customer support (“PCS”), the total fees from the arrangement should be allocated among the elements based on vendor-specific objective evidence of fair value. The fair value of the PCS should be determined by reference to the price the customer will be required to pay when it is sold separately. The portion of the fee allocated to PCS should be recognized as revenue ratably over the term of the PCS arrangement, because the PCS services are assumed to be provided ratably. If sufficient vendor-specific objective evidence does not exist to allocate the fee to the separate elements and the only undelivered element is PCS, the entire arrangement fee should be recognized ratably over (a) the contractual PCS period (for those arrangements with explicit rights to PCS) or (b) the period during which PCS is expected to be provided (for those arrangements with implicit rights to PCS) [SOP 97-2R56-58].

Solution

The LC3 million upfront fee is a service fee for granting a third party access to its technology and to keep it updated in accordance with its requirements for a period of three years. The requirement to keep the technology updated is akin to providing an unspecified upgrade/enhancement by analogy to SOP 97-2. Since Simaba would generally not have vendor objective specific fair value for the update requirements, Simba’s management should recognize the non-refundable upfront fee received over a straight-line basis of three years.

Management should recognize the royalty receipts as revenue when earned. If it is material to Simba’s financial statements, the royalty should be presented as a separate class of revenue.
75. Receipts for conducting development

Background

Cezanne, a pharmaceutical research company, contracts with Botticelli to develop a new medical treatment for asthma over a five-year period. Cezanne is engaged only to provide development services and will periodically have to update Botticelli on the results of its work. Botticelli has exclusive rights over the development results. Botticelli will make five annual payments of LC1 million (totalling LC5 million). Half the money is non-refundable, and half is refundable if the new drug does not obtain regulatory approval. Cezanne’s management estimates that the total costs will be LC4 million, and that it will incur those costs equally over the development period, i.e. LC0.8 million per annum.

After year three, the project is going well. Cezanne has spent LC2.4 million and has received the first three instalments totalling LC3.0 million from Botticelli. After year four, the project is still on track. Cezanne has spent LC3.2 million and has received four instalments totalling LC4.0 million from Botticelli. Whether the product will obtain regulatory approval is still uncertain.

Relevant guidance

Revenue is realised and earned when all of the following criteria are met [SAB 0]:

- Persuasive evidence of an arrangement exists;
- Delivery has occurred;
- Price to the buyer is fixed or determinable; and
- Collectibility is reasonably assured.

Revenue should be recognised on a straight-line basis, unless evidence suggests that the revenue is earned or obligations are fulfilled in a different pattern, over the contractual term of the arrangement or the expected period, during which those specified services will be performed, whichever is longer [SAB 104].

How should a pharmaceutical entity recognise revenue for contract development, if the payments received are partially refundable?

Solution

Cezanne should recognise revenue relating to the non-refundable portion of the arrangement based on its accounting policy for such arrangements (i.e. proportional performance) or analogy to EITF 91-6 model (lesser of amount due under the contract or proportional performance to date). Any payments received by Cezanne in excess of the revenue earned to date should be recorded as deferred revenue. Costs incurred by Cezanne relating to the development services should be expensed as incurred.

Under this basic pattern, Cezanne will realise the deferred revenue only when regulatory approval is obtained. Continuing involvement in the compound through complex collaboration or co-promotion arrangements might well cause further deferral over the arrangement terms.
76. Revenue from collaboration arrangements

**Background**

Pollock Corp. and Vermeer enter into a collaboration arrangement. Pollock receives a non-refundable up-front payment for an anti-infective product it has created and which is currently in development. The agreement also allows Pollock to receive non-refundable, success-based milestone payments for further development. In return for these payments, Vermeer will receive the exclusive right to sell the product and will pay Pollock a royalty share of future sales. The cost to market the product is borne by Vermeer.

**Relevant guidance**

In an arrangement with multiple deliverables, the delivered item(s) should be considered a separate unit of accounting if all of the following criteria are met:

- The delivered item(s) has value to the customer on a stand-alone basis
- There is objective and reliable evidence of the fair value of the undelivered elements
- If a general right of return related to the delivered item exists, delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the vendor

Upfront fees, even if non-refundable, are earned as the products and/or services are delivered and/or performed over the term of the arrangement or the expected period of performance and generally should be deferred and recognised systematically over the periods that the fees are earned. A systematic method would be on a straight-line basis, unless evidence suggests that revenue is earned or obligations are fulfilled in a different pattern, in which case that pattern should be followed. Service revenue should be recognised on a straight-line basis, unless evidence suggests that the revenue is earned or obligations are fulfilled in a different pattern, over the contractual term of the arrangement or the expected period during which those specified services will be performed [SAB Topic 13].

**Solution**

Recognition of the collaboration receipts as revenue depends on whether a culmination of an earnings process has occurred. Because the product is still under development and Pollock is providing subsequent development services, the upfront payment cannot be separated from the development services as it does not have standalone value to the customer without the ongoing development services; accordingly, the upfront payment would be deferred and amortised over the expected development period.

Pollock should recognise the milestones as revenue based on its accounting policy applied consistently using one of the four methods discussed in Solution 21.

In these arrangements, consideration must also be given as to whether the contractual payments all represent fair value. If Pollock receives significant milestone premiums and a relatively smaller royalty, the fair values should be assessed, as part of the milestones may need to be deferred since it potentially represents part of the royalty income stream.

How should receipts from collaboration arrangements be accounted for?
Background
CareB owns a new compound and has contracted with Devox to complete the development and apply for regulatory approvals. CareB will make upfront payments and milestone payments to Devox for the development services as required by the contract. CareB will also grant Devox exclusive marketing rights for the drug in Japan, if the development is successful. CareB will retain the marketing and other intellectual rights in the rest of the world and will supply Devox with the drug for sale in Japan at cost plus a normal margin for the production.

Relevant guidance
Revenue is realised and earned when all of the following criteria are met [SAB 0]:
- Persuasive evidence of an arrangement exists;
- Delivery has occurred;
- Price to the buyer is fixed or determinable; and
- Collectibility is reasonably assured.

Revenue should be recognised on a straight-line basis, unless evidence suggests that the revenue is earned or obligations are fulfilled in a different pattern, over the contractual term of the arrangement or the expected period, during which those specified services will be performed, whichever is longer [SAB 104].

When there are multiple elements within an arrangement a determination of the units of accounting need to be made in order to assess the appropriate accounting treatment for each element [EITF 00-21] of the arrangement.

Solution
Because an earnings process has not been completed, Devox would recognise the upfront payment as revenue over the development period.

Milestone receipts should be recorded as revenue in accordance with Devox’s accounting policy and considering the specific circumstances of the arrangement. There are several acceptable methods for recognising milestones including the milestone payment method, an EITF 91-6 performance model, a contingency adjusted performance model, or the completed contract term method. The completed contract term method would be expected to be rare.

Costs incurred by Devox under this development agreement should be classified as cost of services provided as incurred.

In these arrangements, consideration must also be given as to whether the contractual payments all represent fair value. If CareB makes significant milestone premiums but receives an abnormal supply premium, the fair values should be assessed, and part of the milestone may need to be deferred as it potentially represents part of the supply contract.

How should payments received from a third party to conduct development activities be recognised where the development company has continuing involvement with the product?
Background
Kandinsky Medical recently completed a major study comparing its Alzheimer’s drug to competing drugs. The results of the study were highly favourable and Kandinsky has invested in a significant new marketing campaign. The campaign will be launched at the January 20X5 International Alzheimer’s Conference. Kandinsky has also paid for direct-to-consumer (DTC) television advertising, which will appear in February 20X5. Related DTC internet advertising will likewise begin in February, and will be paid based on ‘click-through’ to its Alzheimer’s site. How should the marketing campaign costs incurred be treated in its December 20X4 financial statements?

Relevant guidance
The costs of advertising should be expensed either as incurred or the first time the advertising takes place except for [SOP 93-7]:

a. Direct-response advertising (1) whose primary purpose is to elicit sales to customers who could be shown to have responded specifically to the advertising and (2) that results in probable future economic benefits (future benefits). Examples of the first time advertising takes place include the first public showing of a television commercial for its intended purpose and the first appearance of a magazine advertisement for its intended purpose.

b. Expenditures for advertising costs that are made subsequent to recognising revenues related to those costs.

How should expenditure on advertising and promotional campaigns be treated before the campaign is launched?

Solution
Advertising and promotional expenditure (including all costs to develop and produce the marketing campaign and related materials, including the television and internet advertisements) should be treated as an expense when incurred or the first-time the advertisement takes place, whichever is the Company’s consistently applied policy. Costs to develop the Kandinsky’s Medical Alzheimer’s website should either be capitalised or expensed based on the criteria in EITF 00-2. Amounts paid to television broadcast providers should be accounted for as a prepayment and expensed when the advertisement airs in 20X5. Costs for hits to the company’s internet site should be expensed based upon the click-through rate in 20X5.

Please note that the above solution assumes the advertising and promotional activities would be deemed to be “Other than Direct Response Advertising” under SOP 93-7.
Background
Manet Corp. is a pharmaceutical company with several segments. Eighteen percent of the segment expenses in the biotech segment are R&D. Thirty percent of all segment capital expenditure is capitalised R&D costs.

Relevant guidance
Disclosure shall be made in the financial statements of the total research and development costs charged to expense in each period for which an income statement is presented [FAS R.]
The following should be disclosed about each reportable segment if the specified amounts (a) are included in the determination of segment assets reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in the determination of segment assets:

a. The amount of investment in equity method investees
b. Total expenditures for additions to long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets. [FAS 131R.26]

An enterprise shall disclose the following general information [FAS 131R.26]:

a. Factors used to identify the enterprise’s reportable segments, including the basis of organisation (for example, whether management has chosen to organise the enterprise around differences in products and services, geographic areas, regulatory environments, or a combination of factors and whether operating segments have been aggregated)
b. Types of products and services from which each reportable segment derives its revenues.

Solution
Although not technically required to be presented, R&D is typically a key element in a pharmaceutical company’s segment performance, thus, footnote disclosure of R&D expense by segment is recommended. Disclosure is required in the financial statements of the total research and development costs charged to expense in each period for which an income statement is presented. Magnet Corp. should also consider whether discussion of research and development costs by segments is appropriate in Management’s Discussion and Analysis.
Background
Goya Laboratories is eager to increase knowledge of its new generic pain medication within hospitals. Accordingly, Goya’s sales force distributes free samples of the pain medication during sales calls and at certain hospital conventions. Additionally, Goya runs a special promotion where hospitals get 13 tablets for the price of 12.

Relevant guidance
Revenues from the sales of products, services, and other products should be separately disclosed on the face of the income statement. Costs relating to each type of revenue similarly should be reported separately on the face of the income statement. [Regulation S-X Article 5-03]

If the sales incentive is a free product or service at time of sale, the cost should be classified as an expense (cost of sales) by the vendor [EITF 01-09 para.10].

Solution
The cost of product distributed for free and not associated with any specific sale transaction should be classified as an expense according to the Company’s policy which would generally be either marketing expense or cost of sales. Goya should account for the sample product to be given away at conventions and during sales calls as an expense in accordance with the Company’s policy which would generally be either when the product is packaged as sample product or the sample is distributed.

The cost of the incremental 13th tablet sold under the special promotion should be classified as cost of goods sold, as it is related to the overall sales transaction and is not a free sample.
81. Classification of co-promotion royalties

Background
Mondrian Pharma uses the sales force of Matisse Inc. for co-promotion of its transplantation drug in the US. The co-promotion agreement requires that Mondrian pay Matisse 25% of net sales in the US for its marketing efforts. The agreement is material to both parties.

How should pharmaceutical entities classify co-promotion payments and receipts?

Solution
Both Mondrian and Matisse would need to first evaluate the arrangement under EITF 99-19 to determine whether revenue should be presented on a gross or net basis. In this solution, it is assumed that Mondrian is considered the “principal” in the arrangement and Matisse the “agent”.

Mondrian should classify the co-promotion payments as marketing and sales expenses, if expenses are presented by function. If Mondrian presents expenses by nature, the co-promotion payments should be classified as third-party marketing expenses and presented separately on the face of the income statement.

Matisse should classify the co-promotion receipts as a separate class of revenues, if material.

Relevant guidance
Whether a company should recognise revenue on a gross or net basis depends on the relevant facts and circumstances considering the relative strength of the factors or indicators. [EITF 99-19].

If income is derived from more than one source, each class which is not more than 10 percent of the sum of the items may be combined with another class. If these items are combined, related costs and expenses can be combined in the same manner. In addition, revenues from the sale of tangible products and revenues from services should be stated separately. [SEC Regulation S-X 5-03].
82. Presentation of development supplies

Background

Warhol Inc. is developing a new ingredient for a specific drug. It uses several different raw materials in development which have no alternative future use. These supplies are stored directly in the development facilities and are not recorded in inventories.

Relevant guidance

The costs of materials that are acquired or constructed for a particular research and development project and have no alternative future uses (in other research and development projects or otherwise) should be treated as research and development costs at the time the costs are incurred since there are no separate economic values for these materials [FAS 2].

The costs of materials that are acquired or constructed for a particular research and development project and have alternative future uses (in other research and development projects or otherwise) should be capitalised and expensed when used.

Solution

Supplies acquired for use in development activities do not meet the definition of inventory and should not be classified as such. Rather, development supplies should be charged to expense when used in research and development as they have no alternative use. However, if the supplies were going to be used in R&D over a period of time, they could be capitalised as a prepaid asset and expensed over that period (but would not be recorded as inventory).
## Contacts

<table>
<thead>
<tr>
<th>Country</th>
<th>Name</th>
<th>Phone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>Diego Niebuhr</td>
<td>[54] 4850 4705</td>
</tr>
<tr>
<td>Australia</td>
<td>Mark Dow</td>
<td>[61] 2 8266 2243</td>
</tr>
<tr>
<td>Brazil (SOACAT)</td>
<td>Luis Madasi</td>
<td>[55] 11 3674 1520</td>
</tr>
<tr>
<td>Canada</td>
<td>Beverly Lyons</td>
<td>[1] 416 218 1455</td>
</tr>
<tr>
<td>China</td>
<td>Feng Xiao</td>
<td>[86] 6123 2699</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>Stephen Booth</td>
<td>[420] 2 5115 2888</td>
</tr>
<tr>
<td></td>
<td>Radmila Fortova</td>
<td>[420] 2 5115 2521</td>
</tr>
<tr>
<td>Denmark</td>
<td>Torben TOJ Jensen</td>
<td>[45] 3945 9243</td>
</tr>
<tr>
<td>Finland</td>
<td>Janne Rajalahti</td>
<td>[358] 3 3138 8016</td>
</tr>
<tr>
<td></td>
<td>Johan Kronberg</td>
<td>[358] 9 2280 1253</td>
</tr>
<tr>
<td>France</td>
<td>Jacques Denizeau</td>
<td>[33] 1 56 57 10 55</td>
</tr>
<tr>
<td>Germany</td>
<td>Philip Marshall</td>
<td>[49] 69 9585 1893</td>
</tr>
<tr>
<td></td>
<td>Klaus Hofer</td>
<td>[49] 69 9585 1496</td>
</tr>
<tr>
<td>Hungary</td>
<td>Ágnes Tardos</td>
<td>[36] 1 461 9149</td>
</tr>
<tr>
<td>India</td>
<td>Thomas Mathew</td>
<td>[91] 22 6669 1234</td>
</tr>
<tr>
<td>Ireland</td>
<td>Enda McDonagh</td>
<td>[353] 1 792 8728</td>
</tr>
<tr>
<td>Israel</td>
<td>Assaf Shemer</td>
<td>[972] 3 795 4671</td>
</tr>
<tr>
<td>Italy</td>
<td>Massimo Dal Lago</td>
<td>[39] 045 8002561</td>
</tr>
<tr>
<td>Japan</td>
<td>Kenichiro Abe</td>
<td>[81] 80 3158 5929</td>
</tr>
<tr>
<td>Mexico</td>
<td>Jorge Luis Hernández Baptista</td>
<td>[52] 55 5263 6106</td>
</tr>
<tr>
<td>Netherlands</td>
<td>Arwin van der Linden</td>
<td>[31] 20 5684712</td>
</tr>
<tr>
<td>Poland</td>
<td>Mariusz Ignatowicz</td>
<td>[48] 22 523 4795</td>
</tr>
<tr>
<td></td>
<td>Antoni Tyminski</td>
<td>[48] 61 850 5103</td>
</tr>
<tr>
<td>Portugal</td>
<td>César Gonçalves</td>
<td>[351] 213 599 436</td>
</tr>
<tr>
<td>Russia</td>
<td>Christian Ziegler</td>
<td>[7] 495 232 5461</td>
</tr>
<tr>
<td></td>
<td>Alina Lavrentieva</td>
<td>[7] 495 967 6250</td>
</tr>
<tr>
<td>South Africa</td>
<td>Denis von Hoesslin</td>
<td>[27] 117 974 285</td>
</tr>
<tr>
<td>Spain</td>
<td>Luis Sánchez Quintana</td>
<td>[34] 91 568 4287</td>
</tr>
<tr>
<td>Sweden</td>
<td>Liselott Stenuudd</td>
<td>[46] 8 555 33 405</td>
</tr>
<tr>
<td>Switzerland</td>
<td>Clive Bellingham</td>
<td>[41] 58 792 2822</td>
</tr>
<tr>
<td></td>
<td>Peter Kartscher</td>
<td>[41] 58 792 5630</td>
</tr>
<tr>
<td></td>
<td>Robert Muir</td>
<td>[41] 61 270 5417</td>
</tr>
<tr>
<td>Turkey</td>
<td>Zeki Gündüz</td>
<td>[90] 212 326 6060</td>
</tr>
<tr>
<td></td>
<td>Ediz Gunsel</td>
<td>[90] 212 326 6160</td>
</tr>
<tr>
<td>UK</td>
<td>Simon Friend</td>
<td>[44] 20 7213 4875</td>
</tr>
<tr>
<td></td>
<td>Mary Dolson</td>
<td>[44] 20 7804 2930</td>
</tr>
<tr>
<td></td>
<td>Stephanie Hyde</td>
<td>[44] 1895 52 2246</td>
</tr>
<tr>
<td>US</td>
<td>Mark Simon</td>
<td>[1] 973 236 5410</td>
</tr>
<tr>
<td></td>
<td>Gerry Flynn</td>
<td>[1] 973 236 5409</td>
</tr>
</tbody>
</table>
The member firms of the PricewaterhouseCoopers network provide industry-focused assurance, tax and advisory services to build public trust and enhance value for its clients and their stakeholders. More than 146,000 people in 150 countries across our network share their thinking, experience and solutions to develop fresh perspectives and practical advice.

This publication has been prepared for general guidance on matters of interest only, and does not constitute professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is given as to the accuracy or completeness of the information contained in this publication, and, to the extent permitted by law, PricewaterhouseCoopers does not accept or assume any liability, responsibility or duty of care for any consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.